{"name":"AstraZeneca","slug":"astrazeneca","ticker":"AZN","exchange":"NASDAQ","domain":"astrazeneca.com","description":"AstraZeneca plc (AZ) is a Swedish-British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.","hq":"Cambridge, UK","founded":0,"employees":"96100","ceo":"Pascal Soriot","sector":"Big Pharma","stockPrice":204.91,"stockChange":4.1,"stockChangePercent":2.04,"marketCap":"$317.7B","metrics":{"revenue":58738999296,"revenueGrowth":4.1,"grossMargin":81.7,"rdSpend":0,"netIncome":10225000448,"cash":5719000064,"dividendYield":1.56,"peRatio":31.3,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Farxiga","genericName":"DAPAGLIFLOZIN","slug":"dapagliflozin","revenue":6300000000,"yoyGrowth":0,"percentOfTotal":16.3},{"name":"Tagrisso","genericName":"osimertinib","slug":"osimertinib","revenue":5800000000,"yoyGrowth":0,"percentOfTotal":15},{"name":"Ultomiris","genericName":"RAVULIZUMAB","slug":"ravulizumab","revenue":5100000000,"yoyGrowth":0,"percentOfTotal":13.2},{"name":"Imfinzi","genericName":"durvalumab","slug":"durvalumab","revenue":4900000000,"yoyGrowth":0,"percentOfTotal":12.7},{"name":"Calquence","genericName":"ACALABRUTINIB","slug":"acalabrutinib","revenue":3100000000,"yoyGrowth":0,"percentOfTotal":8},{"name":"Pulmicort Respules","genericName":"BUDESONIDE","slug":"budesonide","revenue":2800000000,"yoyGrowth":0,"percentOfTotal":7.2},{"name":"Lynparza","genericName":"olaparib","slug":"olaparib","revenue":2600000000,"yoyGrowth":0,"percentOfTotal":6.7},{"name":"Fasenra","genericName":"BENRALIZUMAB","slug":"benralizumab","revenue":1800000000,"yoyGrowth":0,"percentOfTotal":4.7},{"name":"Opsumit","genericName":"MACITENTAN","slug":"macitentan","revenue":1181000000,"yoyGrowth":0,"percentOfTotal":3.1},{"name":"Brilinta","genericName":"ticagrelor","slug":"ticagrelor","revenue":1100000000,"yoyGrowth":0,"percentOfTotal":2.8},{"name":"Prilosec","genericName":"omeprazole","slug":"omeprazole","revenue":1041000000,"yoyGrowth":0,"percentOfTotal":2.7},{"name":"Beyfortus","genericName":"NIRSEVIMAB","slug":"nirsevimab","revenue":800000000,"yoyGrowth":0,"percentOfTotal":2.1},{"name":"Tezspire","genericName":"AMG 157","slug":"amg-157","revenue":800000000,"yoyGrowth":0,"percentOfTotal":2.1},{"name":"Saphnelo","genericName":"ANIFROLUMAB","slug":"anifrolumab","revenue":700000000,"yoyGrowth":0,"percentOfTotal":1.8},{"name":"Imjudo","genericName":"TREMELIMUMAB","slug":"tremelimumab","revenue":400000000,"yoyGrowth":0,"percentOfTotal":1},{"name":"Lumoxiti","genericName":"MOXETUMOMAB PASUDOTOX","slug":"moxetumomab-pasudotox","revenue":205000000,"yoyGrowth":0,"percentOfTotal":0.5}],"timeline":[{"date":"1961-01-01","label":"Endep first approved","drug":"Endep","drugSlug":"amitriptyline","type":"approval","sentiment":"positive"},{"date":"1977-12-30","label":"Nolvadex first approved","drug":"Nolvadex","drugSlug":"tamoxifen","type":"approval","sentiment":"positive"},{"date":"1989-09-14","label":"Prilosec first approved","drug":"Prilosec","drugSlug":"omeprazole","type":"approval","sentiment":"positive"},{"date":"1991-01-01","label":"Plendil first approved","drug":"Plendil","drugSlug":"felodipine","type":"approval","sentiment":"positive"},{"date":"1994-01-01","label":"Pulmicort Respules first approved","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"approval","sentiment":"positive"},{"date":"1995-12-27","label":"Arimidex first approved","drug":"Arimidex","drugSlug":"anastrozole","type":"approval","sentiment":"positive"},{"date":"1997-01-01","label":"Zomig first approved","drug":"Zomig","drugSlug":"zolmitriptan","type":"approval","sentiment":"positive"},{"date":"2002-01-01","label":"Faslodex first approved","drug":"Faslodex","drugSlug":"fulvestrant","type":"approval","sentiment":"positive"},{"date":"2003-01-01","label":"Crestor first approved","drug":"Crestor","drugSlug":"rosuvastatin","type":"approval","sentiment":"positive"},{"date":"2005-01-01","label":"Byetta first approved","drug":"Byetta","drugSlug":"exenatide","type":"approval","sentiment":"positive"},{"date":"2005-01-01","label":"Byetta first approved","drug":"Byetta","drugSlug":"byetta","type":"approval","sentiment":"positive"},{"date":"2013-01-01","label":"Opsumit first approved","drug":"Opsumit","drugSlug":"macitentan","type":"approval","sentiment":"positive"},{"date":"2014-01-01","label":"Farxiga first approved","drug":"Farxiga","drugSlug":"dapagliflozin","type":"approval","sentiment":"positive"},{"date":"2014-01-01","label":"Lynparza first approved","drug":"Lynparza","drugSlug":"olaparib","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Tagrisso first approved","drug":"Tagrisso","drugSlug":"osimertinib","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Uptravi first approved","drug":"Uptravi","drugSlug":"selexipag","type":"approval","sentiment":"positive"},{"date":"2017-01-01","label":"Imfinzi first approved","drug":"Imfinzi","drugSlug":"durvalumab","type":"approval","sentiment":"positive"},{"date":"2017-01-01","label":"Calquence first approved","drug":"Calquence","drugSlug":"acalabrutinib","type":"approval","sentiment":"positive"},{"date":"2017-01-01","label":"Fasenra first approved","drug":"Fasenra","drugSlug":"benralizumab","type":"approval","sentiment":"positive"},{"date":"2018-01-01","label":"Ultomiris first approved","drug":"Ultomiris","drugSlug":"ravulizumab","type":"approval","sentiment":"positive"},{"date":"2018-01-01","label":"Lumoxiti first approved","drug":"Lumoxiti","drugSlug":"moxetumomab-pasudotox","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Koselugo first approved","drug":"Koselugo","drugSlug":"selumetinib","type":"approval","sentiment":"positive"},{"date":"2021-01-01","label":"Tezspire first approved","drug":"Tezspire","drugSlug":"amg-157","type":"approval","sentiment":"positive"},{"date":"2021-01-01","label":"Saphnelo first approved","drug":"Saphnelo","drugSlug":"anifrolumab","type":"approval","sentiment":"positive"},{"date":"2022-01-01","label":"Imjudo first approved","drug":"Imjudo","drugSlug":"tremelimumab","type":"approval","sentiment":"positive"},{"date":"2023-01-01","label":"Beyfortus first approved","drug":"Beyfortus","drugSlug":"nirsevimab","type":"approval","sentiment":"positive"},{"date":"2025-01-01","label":"Wainua first approved","drug":"Wainua","drugSlug":"eplontersen","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-08-27","label":"Imjudo PHASE3 readout","drug":"Imjudo","drugSlug":"tremelimumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-09-09","label":"Calquence PHASE2 readout","drug":"Calquence","drugSlug":"acalabrutinib","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-11-09","label":"Pulmicort Respules patent expiry (Method of Use)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2026-11-09","label":"Pulmicort Respules patent expiry (Method of Use)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2026-11-09","label":"Pulmicort Respules patent expiry (Method of Use)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2026-11-09","label":"Pulmicort Respules patent expiry (Formulation)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2026-11-09","label":"Pulmicort Respules patent expiry (Formulation)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2026-11-09","label":"Pulmicort Respules patent expiry (Formulation)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2026-12-31","label":"Faslodex PHASE3 readout","drug":"Faslodex","drugSlug":"fulvestrant","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-01","label":"Calquence PHASE3 readout","drug":"Calquence","drugSlug":"acalabrutinib","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-11-15","label":"Imjudo PHASE3 readout","drug":"Imjudo","drugSlug":"tremelimumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-12-01","label":"Faslodex PHASE3 readout","drug":"Faslodex","drugSlug":"fulvestrant","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-12-31","label":"Brilinta Phase 3 readout (Acute Ischemic Stroke, Clopidogrel Resistance)","drug":"Brilinta","drugSlug":"ticagrelor","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-12-31","label":"Prilosec Phase 2 readout (Crohn Disease (CD))","drug":"Prilosec","drugSlug":"omeprazole","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-08-29","label":"Lynparza PHASE3 readout","drug":"Lynparza","drugSlug":"olaparib","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-09-24","label":"Lynparza patent expiry (Compound)","drug":"Lynparza","drugSlug":"olaparib","type":"patent_expiry","sentiment":"negative"},{"date":"2028-11-12","label":"Pulmicort Respules patent expiry (Method of Use)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2028-11-22","label":"Pulmicort Respules patent expiry (Formulation)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2029-02-01","label":"Arimidex Phase 3 readout (ER-Positive HER2-Negative Breast Cancer)","drug":"Arimidex","drugSlug":"anastrozole","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-05-07","label":"Pulmicort Respules patent expiry (Formulation)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2029-08-01","label":"Pulmicort Respules patent expiry (Formulation)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2029-08-03","label":"Pulmicort Respules patent expiry (Method of Use)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2030-03-31","label":"Prilosec Phase 3 readout (Helicobacter Pylori)","drug":"Prilosec","drugSlug":"omeprazole","type":"phase3_readout","sentiment":"neutral"},{"date":"2030-03-31","label":"Arimidex Phase 3 readout (Breast Cancer)","drug":"Arimidex","drugSlug":"anastrozole","type":"phase3_readout","sentiment":"neutral"},{"date":"2030-03-31","label":"Nolvadex Phase 3 readout (Breast Cancer)","drug":"Nolvadex","drugSlug":"tamoxifen","type":"phase3_readout","sentiment":"neutral"},{"date":"2030-04-17","label":"Brilinta patent expiry (Formulation)","drug":"Brilinta","drugSlug":"ticagrelor","type":"patent_expiry","sentiment":"negative"},{"date":"2030-05-16","label":"Nolvadex Phase 3 readout (Mastalgia)","drug":"Nolvadex","drugSlug":"tamoxifen","type":"phase3_readout","sentiment":"neutral"},{"date":"2030-10-01","label":"Arimidex Phase 3 readout (Breast Cancer Female)","drug":"Arimidex","drugSlug":"anastrozole","type":"phase3_readout","sentiment":"neutral"},{"date":"2030-10-01","label":"Nolvadex Phase 3 readout (Breast Cancer Female)","drug":"Nolvadex","drugSlug":"tamoxifen","type":"phase3_readout","sentiment":"neutral"},{"date":"2030-10-17","label":"Brilinta patent expiry (Compound)","drug":"Brilinta","drugSlug":"ticagrelor","type":"patent_expiry","sentiment":"negative"},{"date":"2031-09-07","label":"Pulmicort Respules patent expiry (Formulation)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2031-09-07","label":"Pulmicort Respules patent expiry (Formulation)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2031-09-07","label":"Pulmicort Respules patent expiry (Formulation)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2031-09-07","label":"Pulmicort Respules patent expiry (Formulation)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2031-09-07","label":"Pulmicort Respules patent expiry (Formulation)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2032-03-01","label":"Arimidex Phase 3 readout (Breast Neoplasms)","drug":"Arimidex","drugSlug":"anastrozole","type":"phase3_readout","sentiment":"neutral"},{"date":"2032-03-01","label":"Nolvadex Phase 3 readout (Breast Neoplasms)","drug":"Nolvadex","drugSlug":"tamoxifen","type":"phase3_readout","sentiment":"neutral"},{"date":"2034-02-14","label":"Faslodex patent expiry (Formulation)","drug":"Faslodex","drugSlug":"fulvestrant","type":"patent_expiry","sentiment":"negative"},{"date":"2034-02-14","label":"Faslodex patent expiry (Formulation)","drug":"Faslodex","drugSlug":"fulvestrant","type":"patent_expiry","sentiment":"negative"},{"date":"2034-05-17","label":"Faslodex patent expiry (Formulation)","drug":"Faslodex","drugSlug":"fulvestrant","type":"patent_expiry","sentiment":"negative"},{"date":"2036-01-27","label":"Brilinta patent expiry (Method of Use)","drug":"Brilinta","drugSlug":"ticagrelor","type":"patent_expiry","sentiment":"negative"},{"date":"2036-07-27","label":"Brilinta patent expiry (Compound)","drug":"Brilinta","drugSlug":"ticagrelor","type":"patent_expiry","sentiment":"negative"},{"date":"2036-08-01","label":"Nolvadex Phase 3 readout (Breast Cancer, Adjuvant Drug Therapy)","drug":"Nolvadex","drugSlug":"tamoxifen","type":"phase3_readout","sentiment":"neutral"},{"date":"2036-09-09","label":"Pulmicort Respules patent expiry (Formulation)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2036-09-09","label":"Pulmicort Respules patent expiry (Method of Use)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2036-12-08","label":"Prilosec patent expiry (Formulation)","drug":"Prilosec","drugSlug":"omeprazole","type":"patent_expiry","sentiment":"negative"},{"date":"2036-12-08","label":"Prilosec patent expiry (Formulation)","drug":"Prilosec","drugSlug":"omeprazole","type":"patent_expiry","sentiment":"negative"},{"date":"2039-01-10","label":"Pulmicort Respules patent expiry (Method of Use)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2039-01-10","label":"Pulmicort Respules patent expiry (Formulation)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2043-01-23","label":"Pulmicort Respules patent expiry (Method of Use)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2043-01-23","label":"Pulmicort Respules patent expiry (Method of Use)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2043-01-23","label":"Pulmicort Respules patent expiry (Formulation)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2043-01-23","label":"Pulmicort Respules patent expiry (Formulation)","drug":"Pulmicort Respules","drugSlug":"budesonide","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Prilosec patent cliff ($1.5B at risk)","drug":"Prilosec","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Arimidex patent cliff ($1.2B at risk)","drug":"Arimidex","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"Nexium patent cliff ($2.5B at risk)","drug":"Nexium","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":17005000000,"percentOfTotal":44,"drugCount":70,"colorKey":"immunology","drugs":[{"name":"Tagrisso","genericName":"osimertinib","slug":"osimertinib","indication":"Adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations","status":"marketed","revenue":5800000000},{"name":"Imfinzi","genericName":"durvalumab","slug":"durvalumab","indication":"Extensive stage primary small cell carcinoma of lung","status":"marketed","revenue":4900000000},{"name":"Calquence","genericName":"ACALABRUTINIB","slug":"acalabrutinib","indication":"Chronic lymphocyticleukemia/small lymphocytic lymphoma","status":"marketed","revenue":3100000000},{"name":"Lynparza","genericName":"olaparib","slug":"olaparib","indication":"BRCA mutation-positive and HER2-negative breast cancer","status":"marketed","revenue":2600000000},{"name":"Imjudo","genericName":"TREMELIMUMAB","slug":"tremelimumab","indication":"Liver cell carcinoma","status":"marketed","revenue":400000000},{"name":"Lumoxiti","genericName":"MOXETUMOMAB PASUDOTOX","slug":"moxetumomab-pasudotox","indication":"Hairy cell leukemia","status":"marketed","revenue":205000000},{"name":"Arimidex","genericName":"anastrozole","slug":"anastrozole","indication":"Adjuvant treatment of early breast cancer","status":"marketed"},{"name":"Faslodex","genericName":"fulvestrant","slug":"fulvestrant","indication":"Metastatic Breast Cancer Progression Post-Antiestrogen Therapy","status":"marketed"},{"name":"Nolvadex","genericName":"tamoxifen","slug":"tamoxifen","indication":"Carcinoma of female breast","status":"marketed"},{"name":"arimidex dummy","genericName":"arimidex dummy","slug":"arimidex-dummy","indication":"Treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy","status":"phase_3"},{"name":"AC2592","genericName":"AC2592","slug":"ac2592","indication":"Treatment of relapsed or refractory follicular lymphoma","status":"phase_2"},{"name":"AZD 1775","genericName":"AZD 1775","slug":"azd-1775","indication":"Advanced solid tumors","status":"phase_1"},{"name":"AZD0120","genericName":"AZD0120","slug":"azd0120","indication":"FGFR1-amplified or FGFR1-altered solid tumors","status":"phase_3"},{"name":"AZD3241","genericName":"AZD3241","slug":"azd3241","indication":"Relapsed or refractory chronic lymphocytic leukemia (CLL)","status":"phase_2"},{"name":"AZD4144","genericName":"AZD4144","slug":"azd4144","indication":"Relapsed or refractory chronic lymphocytic leukemia (CLL)","status":"phase_2"},{"name":"AZD4635","genericName":"AZD4635","slug":"azd4635","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"AZD5423","genericName":"AZD5423","slug":"azd5423","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_2"},{"name":"AZD6234","genericName":"AZD6234","slug":"azd6234","indication":"Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)","status":"phase_2"},{"name":"AZD9291 Dosing","genericName":"AZD9291 Dosing","slug":"azd9291-dosing","indication":"Non-small cell lung cancer with EGFR T790M mutation after progression on first- or second-generation EGFR inhibitors","status":"phase_3"},{"name":"AZD9567","genericName":"AZD9567","slug":"azd9567","indication":"Relapsed or refractory chronic lymphocytic leukemia (CLL)","status":"phase_2"},{"name":"Dato-DXd","genericName":"Dato-DXd","slug":"dato-dxd","indication":"Metastatic or unresectable gastric cancer","status":"phase_3"},{"name":"Tamoxifen (Nolvadex)","genericName":"Tamoxifen (Nolvadex)","slug":"tamoxifen-nolvadex","indication":"Adjuvant treatment of breast cancer in postmenopausal women with estrogen receptor-positive disease","status":"phase_3"},{"name":"Tremelimumab (Regimen 2)","genericName":"Tremelimumab (Regimen 2)","slug":"tremelimumab-regimen-2","indication":"Unresectable or metastatic melanoma (in combination with durvalumab)","status":"phase_3"},{"name":"5-flourouracil","genericName":"5-flourouracil","slug":"5-flourouracil","indication":"Adjuvant treatment of colon cancer","status":"phase_2"},{"name":"ABT-143","genericName":"ABT-143","slug":"abt-143","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"ARIMIDEX (anastrazole)","genericName":"ARIMIDEX (anastrazole)","slug":"arimidex-anastrazole","indication":"Hormone receptor-positive early-stage breast cancer in postmenopausal women (adjuvant therapy)","status":"phase_3"},{"name":"AZD0171","genericName":"AZD0171","slug":"azd0171","indication":"Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)","status":"phase_2"},{"name":"AZD0292","genericName":"AZD0292","slug":"azd0292","indication":"Relapsed or refractory chronic lymphocytic leukemia","status":"phase_2"},{"name":"AZD0486","genericName":"AZD0486","slug":"azd0486","indication":"Advanced or metastatic solid tumors with mTOR pathway activation","status":"phase_3"},{"name":"AZD1152 part B","genericName":"AZD1152 part B","slug":"azd1152-part-b","indication":"Solid tumors","status":"phase_1"},{"name":"AZD2281","genericName":"AZD2281","slug":"azd2281","indication":"Ovarian cancer","status":"phase_2"},{"name":"AZD2816","genericName":"AZD2816","slug":"azd2816","indication":"Relapsed or refractory chronic lymphocytic leukemia (CLL)","status":"phase_2"},{"name":"AZD5004","genericName":"AZD5004","slug":"azd5004","indication":"Hepatocellular carcinoma (HCC), FGFR4-positive","status":"phase_2"},{"name":"AZD5148","genericName":"AZD5148","slug":"azd5148","indication":"Multiple myeloma","status":"phase_2"},{"name":"AZD5335","genericName":"AZD5335","slug":"azd5335","indication":"FGFR1-amplified or FGFR1-driven solid tumors (in development)","status":"phase_3"},{"name":"AZD5363when combined with weekly paclitaxel.","genericName":"AZD5363when combined with weekly paclitaxel.","slug":"azd5363when-combined-with-weekly-paclitaxel","indication":"Triple-negative breast cancer","status":"phase_1"},{"name":"AZD5851","genericName":"AZD5851","slug":"azd5851","indication":"Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)","status":"phase_2"},{"name":"AZD6234 in combination with AZD9550","genericName":"AZD6234 in combination with AZD9550","slug":"azd6234-in-combination-with-azd9550","indication":"Metastatic non-small cell lung cancer","status":"phase_2"},{"name":"AZD6244 Dosing Period 1","genericName":"AZD6244 Dosing Period 1","slug":"azd6244-dosing-period-1","indication":"Non-small cell lung cancer","status":"phase_1"},{"name":"AZD6244 Dosing Period 2","genericName":"AZD6244 Dosing Period 2","slug":"azd6244-dosing-period-2","indication":"Non-small cell lung cancer","status":"phase_1"},{"name":"AZD6244 Dosing Period 3","genericName":"AZD6244 Dosing Period 3","slug":"azd6244-dosing-period-3","indication":"Non-small cell lung cancer","status":"phase_1"},{"name":"AZD6244 Dosing Period 4","genericName":"AZD6244 Dosing Period 4","slug":"azd6244-dosing-period-4","indication":"Advanced solid tumors with RAS or BRAF mutations","status":"phase_1"},{"name":"AZD6738 and olaparib","genericName":"AZD6738 and olaparib","slug":"azd6738-and-olaparib","indication":"Ovarian cancer","status":"phase_2"},{"name":"AZD8529","genericName":"AZD8529","slug":"azd8529","indication":"Multiple myeloma","status":"phase_2"},{"name":"AZD8835 in combination with fulvestrant","genericName":"AZD8835 in combination with fulvestrant","slug":"azd8835-in-combination-with-fulvestrant","indication":"Hormone receptor-positive breast cancer","status":"phase_1"},{"name":"AZD8871","genericName":"AZD8871","slug":"azd8871","indication":"Relapsed or refractory chronic lymphocytic leukemia (CLL)","status":"phase_2"},{"name":"AZD9550","genericName":"AZD9550","slug":"azd9550","indication":"Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)","status":"phase_2"},{"name":"AZD9833","genericName":"AZD9833","slug":"azd9833","indication":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer","status":"phase_3"},{"name":"AZD9833 with abemaciclib","genericName":"AZD9833 with abemaciclib","slug":"azd9833-with-abemaciclib","indication":"Breast cancer","status":"phase_1"},{"name":"AZD9833 with anastrozole","genericName":"AZD9833 with anastrozole","slug":"azd9833-with-anastrozole","indication":"Hormone receptor-positive breast cancer","status":"phase_1"},{"name":"AZD9833 with capivasertib","genericName":"AZD9833 with capivasertib","slug":"azd9833-with-capivasertib","indication":"Breast cancer","status":"phase_1"},{"name":"AZD9833 with everolimus","genericName":"AZD9833 with everolimus","slug":"azd9833-with-everolimus","indication":"Breast cancer","status":"phase_1"},{"name":"AZD9833 with palbociclib","genericName":"AZD9833 with palbociclib","slug":"azd9833-with-palbociclib","indication":"Breast cancer","status":"phase_1"},{"name":"Abiraterone + Prednisolone/Prednisone","genericName":"Abiraterone + Prednisolone/Prednisone","slug":"abiraterone-prednisolone-prednisone","indication":"Metastatic castration-resistant prostate cancer (mCRPC)","status":"phase_3"},{"name":"Abraxane + carboplatin","genericName":"Abraxane + carboplatin","slug":"abraxane-carboplatin","indication":"Non-small cell lung cancer (NSCLC)","status":"phase_3"},{"name":"Acalabrutinib Treatment A","genericName":"Acalabrutinib Treatment A","slug":"acalabrutinib-treatment-a","indication":"Chronic lymphocytic leukemia","status":"phase_1"},{"name":"Acalabrutinib Treatment C","genericName":"Acalabrutinib Treatment C","slug":"acalabrutinib-treatment-c","indication":"Chronic lymphocytic leukemia","status":"phase_1"},{"name":"Acalabrutinib Treatment D","genericName":"Acalabrutinib Treatment D","slug":"acalabrutinib-treatment-d","indication":"Chronic lymphocytic leukemia","status":"phase_1"},{"name":"Acalabrutinib capsule","genericName":"Acalabrutinib capsule","slug":"acalabrutinib-capsule","indication":"Chronic lymphocytic leukemia (CLL)","status":"marketed"},{"name":"Acalabrutinib combination with Rituximab","genericName":"Acalabrutinib combination with Rituximab","slug":"acalabrutinib-combination-with-rituximab","indication":"Chronic lymphocytic leukemia","status":"phase_2"},{"name":"Acalabrutinib monotherapy","genericName":"Acalabrutinib monotherapy","slug":"acalabrutinib-monotherapy","indication":"Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy","status":"phase_2"},{"name":"Active Comparator: Olaparib tablets","genericName":"Active Comparator: Olaparib tablets","slug":"active-comparator-olaparib-tablets","indication":"BRCA-mutant metastatic breast cancer","status":"phase_3"},{"name":"Administration of AZD6738","genericName":"Administration of AZD6738","slug":"administration-of-azd6738","indication":"Solid tumors with defective DNA damage response pathways","status":"phase_1"},{"name":"Administration of ceralasertib and olaparib","genericName":"Administration of ceralasertib and olaparib","slug":"administration-of-ceralasertib-and-olaparib","indication":"Breast cancer","status":"phase_1"},{"name":"Administration of ceralasertib monotherapy","genericName":"Administration of ceralasertib monotherapy","slug":"administration-of-ceralasertib-monotherapy","indication":"Advanced solid tumors","status":"phase_1"},{"name":"Anastozole (Arimidex)","genericName":"Anastozole (Arimidex)","slug":"anastozole-arimidex","indication":"Adjuvant treatment of hormone receptor-positive early-stage breast cancer in postmenopausal women","status":"phase_3"},{"name":"Anastrazole","genericName":"Anastrazole","slug":"anastrazole","indication":"Hormone receptor positive malignant neoplasm of breast","status":"marketed"},{"name":"Anastrazole (Arimidex)","genericName":"Anastrazole (Arimidex)","slug":"anastrazole-arimidex","indication":"Adjuvant treatment of hormone receptor-positive early-stage breast cancer in postmenopausal women","status":"phase_3"},{"name":"Anastrozole and goserelin","genericName":"Anastrozole and goserelin","slug":"anastrozole-and-goserelin","indication":"Breast cancer","status":"phase_2"},{"name":"Biological: AZD3152","genericName":"Biological: AZD3152","slug":"biological-azd3152","indication":"Non-small cell lung cancer","status":"phase_2"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":8581000000,"percentOfTotal":22.2,"drugCount":15,"colorKey":"oncology","drugs":[{"name":"Farxiga","genericName":"DAPAGLIFLOZIN","slug":"dapagliflozin","indication":"Chronic heart failure","status":"marketed","revenue":6300000000},{"name":"Opsumit","genericName":"MACITENTAN","slug":"macitentan","indication":"Pulmonary arterial hypertension","status":"marketed","revenue":1181000000},{"name":"Brilinta","genericName":"ticagrelor","slug":"ticagrelor","indication":"Acute coronary syndrome","status":"marketed","revenue":1100000000},{"name":"Crestor","genericName":"rosuvastatin","slug":"rosuvastatin","indication":"Arteriosclerotic vascular disease","status":"marketed"},{"name":"Uptravi","genericName":"SELEXIPAG","slug":"selexipag","indication":"Pulmonary arterial hypertension","status":"marketed"},{"name":"AZD4017","genericName":"AZD4017","slug":"azd4017","indication":"Atrial fibrillation for stroke prevention","status":"phase_2"},{"name":"Plendil","genericName":"FELODIPINE","slug":"felodipine","indication":"Hypertensive disorder","status":"marketed"},{"name":"Rosuvastatin; improvement of lipid profile","genericName":"Rosuvastatin; improvement of lipid profile","slug":"rosuvastatin-improvement-of-lipid-profile","indication":"Hypercholesterolemia and mixed dyslipidemia","status":"marketed"},{"name":"ABT-335 and rosuvastatin calcium","genericName":"ABT-335 and rosuvastatin calcium","slug":"abt-335-and-rosuvastatin-calcium","indication":"Dyslipidemia with elevated triglycerides and low HDL cholesterol","status":"phase_3"},{"name":"ACS patients treated with OAP","genericName":"ACS patients treated with OAP","slug":"acs-patients-treated-with-oap","indication":"Treatment of heart failure","status":"phase_2"},{"name":"AZD0901","genericName":"AZD0901","slug":"azd0901","indication":"Pulmonary hypertension","status":"phase_3"},{"name":"Acetylsalicylzuur Apotex Cardio","genericName":"Acetylsalicylzuur Apotex Cardio","slug":"acetylsalicylzuur-apotex-cardio","indication":"Cardiovascular disease prevention","status":"phase_1"},{"name":"Baxdrostat and dapagliflozin","genericName":"Baxdrostat and dapagliflozin","slug":"baxdrostat-and-dapagliflozin","indication":"Heart failure with reduced ejection fraction","status":"phase_3"},{"name":"Baxdrostat/dapagliflozin","genericName":"Baxdrostat/dapagliflozin","slug":"baxdrostat-dapagliflozin","indication":"Heart failure with reduced ejection fraction","status":"phase_3"},{"name":"Brilinta","genericName":"Brilinta","slug":"brilinta","indication":"Acute coronary syndrome","status":"marketed"}]},{"name":"Other","slug":"other","revenue":6141000000,"percentOfTotal":15.9,"drugCount":153,"colorKey":"cardiovascular","drugs":[{"name":"Ultomiris","genericName":"RAVULIZUMAB","slug":"ravulizumab","indication":"Atypical hemolytic uremic syndrome (aHUS)","status":"marketed","revenue":5100000000},{"name":"Prilosec","genericName":"omeprazole","slug":"omeprazole","indication":"Duodenal Ulcer due to H. Pylori","status":"marketed","revenue":1041000000},{"name":"AC2307","genericName":"AC2307","slug":"ac2307","indication":"Other","status":"phase_2"},{"name":"AZD 8529","genericName":"AZD 8529","slug":"azd-8529","indication":"Other","status":"phase_2"},{"name":"AZD0156","genericName":"AZD0156","slug":"azd0156","indication":"Other","status":"phase_1"},{"name":"AZD0305","genericName":"AZD0305","slug":"azd0305","indication":"Other","status":"phase_1"},{"name":"AZD0486 IV","genericName":"AZD0486 IV","slug":"azd0486-iv","indication":"Other","status":"phase_1"},{"name":"AZD0516","genericName":"AZD0516","slug":"azd0516","indication":"Other","status":"phase_1"},{"name":"AZD1163","genericName":"AZD1163","slug":"azd1163","indication":"Other","status":"phase_2"},{"name":"AZD1613","genericName":"AZD1613","slug":"azd1613","indication":"Other","status":"phase_1"},{"name":"AZD2287","genericName":"AZD2287","slug":"azd2287","indication":"Other","status":"phase_1"},{"name":"AZD2962","genericName":"AZD2962","slug":"azd2962","indication":"Other","status":"phase_1"},{"name":"AZD3293 tablet formulation A","genericName":"AZD3293 tablet formulation A","slug":"azd3293-tablet-formulation-a","indication":"Other","status":"phase_1"},{"name":"AZD3293 tablet formulation B","genericName":"AZD3293 tablet formulation B","slug":"azd3293-tablet-formulation-b","indication":"Other","status":"phase_1"},{"name":"AZD3355","genericName":"AZD3355","slug":"azd3355","indication":"Other","status":"phase_2"},{"name":"AZD3632","genericName":"AZD3632","slug":"azd3632","indication":"Other","status":"phase_1"},{"name":"AZD3839","genericName":"AZD3839","slug":"azd3839","indication":"Other","status":"phase_1"},{"name":"AZD3974","genericName":"AZD3974","slug":"azd3974","indication":"Other","status":"phase_1"},{"name":"AZD4063","genericName":"AZD4063","slug":"azd4063","indication":"Other","status":"phase_1"},{"name":"AZD4076","genericName":"AZD4076","slug":"azd4076","indication":"Other","status":"phase_1"},{"name":"AZD4573","genericName":"AZD4573","slug":"azd4573","indication":"Other","status":"phase_2"},{"name":"AZD4785","genericName":"AZD4785","slug":"azd4785","indication":"Other","status":"phase_1"},{"name":"AZD4916","genericName":"AZD4916","slug":"azd4916","indication":"Other","status":"phase_1"},{"name":"AZD4954","genericName":"AZD4954","slug":"azd4954","indication":"Other","status":"phase_1"},{"name":"AZD4956","genericName":"AZD4956","slug":"azd4956","indication":"Other","status":"phase_1"},{"name":"AZD5055 solution for infusion","genericName":"AZD5055 solution for infusion","slug":"azd5055-solution-for-infusion","indication":"Other","status":"phase_1"},{"name":"AZD5312","genericName":"AZD5312","slug":"azd5312","indication":"Other","status":"phase_1"},{"name":"AZD5658","genericName":"AZD5658","slug":"azd5658","indication":"Other","status":"phase_1"},{"name":"AZD6140","genericName":"AZD6140","slug":"azd6140","indication":"Other","status":"phase_1"},{"name":"AZD6482","genericName":"AZD6482","slug":"azd6482","indication":"Other","status":"phase_1"},{"name":"AZD6563","genericName":"AZD6563","slug":"azd6563","indication":"Other","status":"phase_1"},{"name":"AZD6621","genericName":"AZD6621","slug":"azd6621","indication":"Other","status":"phase_1"},{"name":"AZD6793","genericName":"AZD6793","slug":"azd6793","indication":"Other","status":"phase_2"},{"name":"AZD7053","genericName":"AZD7053","slug":"azd7053","indication":"Other","status":"phase_1"},{"name":"AZD7295","genericName":"AZD7295","slug":"azd7295","indication":"Other","status":"phase_1"},{"name":"AZD7687","genericName":"AZD7687","slug":"azd7687","indication":"Other","status":"phase_1"},{"name":"AZD7760","genericName":"AZD7760","slug":"azd7760","indication":"Other","status":"phase_1"},{"name":"AZD7798","genericName":"AZD7798","slug":"azd7798","indication":"Other","status":"phase_2"},{"name":"AZD7986","genericName":"AZD7986","slug":"azd7986","indication":"Other","status":"phase_1"},{"name":"AZD8421","genericName":"AZD8421","slug":"azd8421","indication":"Other","status":"phase_1"},{"name":"AZD8566","genericName":"AZD8566","slug":"azd8566","indication":"Other","status":"phase_1"},{"name":"AZD8701","genericName":"AZD8701","slug":"azd8701","indication":"Other","status":"phase_1"},{"name":"AZD9496","genericName":"AZD9496","slug":"azd9496","indication":"Other","status":"phase_1"},{"name":"AZD9496 Variant B","genericName":"AZD9496 Variant B","slug":"azd9496-variant-b","indication":"Other","status":"phase_1"},{"name":"AZD9574","genericName":"AZD9574","slug":"azd9574","indication":"Other","status":"phase_1"},{"name":"AZD9829","genericName":"AZD9829","slug":"azd9829","indication":"Other","status":"phase_1"},{"name":"AZD9838","genericName":"AZD9838","slug":"azd9838","indication":"Other","status":"phase_1"},{"name":"BMS-512148","genericName":"BMS-512148","slug":"bms-512148","indication":"Other","status":"phase_2"},{"name":"HFA MDI","genericName":"HFA MDI","slug":"hfa-mdi","indication":"Other","status":"phase_3"},{"name":"HFA-134a","genericName":"HFA-134a","slug":"hfa-134a","indication":"Propellant for pressurized metered-dose inhalers delivering bronchodilators, corticosteroids, and other inhaled medications","status":"phase_3"},{"name":"MEDI-545 600","genericName":"MEDI-545 600","slug":"medi-545-600","indication":"Other","status":"phase_2"},{"name":"MITT","genericName":"MITT","slug":"mitt","indication":"Other","status":"marketed"},{"name":"NXY-059","genericName":"NXY-059","slug":"nxy-059","indication":"Acute ischemic stroke (within 6 hours of symptom onset)","status":"phase_3"},{"name":"Proventil 180 μg","genericName":"Proventil 180 μg","slug":"proventil-180-g","indication":"Other","status":"phase_2"},{"name":"Seasonal influenza virus vaccine","genericName":"Seasonal influenza virus vaccine","slug":"seasonal-influenza-virus-vaccine","indication":"Prevention of seasonal influenza disease","status":"phase_3"},{"name":"Symbicort","genericName":"Symbicort","slug":"symbicort","indication":"Other","status":"marketed"},{"name":"pegfiligrastim","genericName":"pegfiligrastim","slug":"pegfiligrastim","indication":"Other","status":"discontinued"},{"name":"AMG 139","genericName":"AMG 139","slug":"amg-139","indication":"Other","status":"phase_1"},{"name":"AR-C165395XX","genericName":"AR-C165395XX","slug":"ar-c165395xx","indication":"Other","status":"phase_1"},{"name":"AS MDI","genericName":"AS MDI","slug":"as-mdi","indication":"Other","status":"phase_3"},{"name":"AS MDI 180 µg","genericName":"AS MDI 180 µg","slug":"as-mdi-180-g","indication":"Other","status":"phase_2"},{"name":"AZD0120 - Regimen 1","genericName":"AZD0120 - Regimen 1","slug":"azd0120-regimen-1","indication":"Other","status":"phase_1"},{"name":"AZD0120 - Regimen 2","genericName":"AZD0120 - Regimen 2","slug":"azd0120-regimen-2","indication":"Other","status":"phase_1"},{"name":"AZD0284","genericName":"AZD0284","slug":"azd0284","indication":"Other","status":"phase_1"},{"name":"AZD0449","genericName":"AZD0449","slug":"azd0449","indication":"Other","status":"phase_1"},{"name":"AZD0754","genericName":"AZD0754","slug":"azd0754","indication":"Other","status":"phase_2"},{"name":"AZD0837","genericName":"AZD0837","slug":"azd0837","indication":"Other","status":"phase_2"},{"name":"AZD0865","genericName":"AZD0865","slug":"azd0865","indication":"Other","status":"phase_2"},{"name":"AZD1152 part A","genericName":"AZD1152 part A","slug":"azd1152-part-a","indication":"Other","status":"phase_1"},{"name":"AZD1613 - Part A","genericName":"AZD1613 - Part A","slug":"azd1613-part-a","indication":"Other","status":"phase_1"},{"name":"AZD1613 - Part B","genericName":"AZD1613 - Part B","slug":"azd1613-part-b","indication":"Other","status":"phase_1"},{"name":"AZD1656","genericName":"AZD1656","slug":"azd1656","indication":"Other","status":"phase_2"},{"name":"AZD1705","genericName":"AZD1705","slug":"azd1705","indication":"Other","status":"phase_1"},{"name":"AZD1940","genericName":"AZD1940","slug":"azd1940","indication":"Other","status":"phase_2"},{"name":"AZD1981, current small-particle tablet","genericName":"AZD1981, current small-particle tablet","slug":"azd1981-current-small-particle-tablet","indication":"Other","status":"phase_1"},{"name":"AZD1981, new large-particle table","genericName":"AZD1981, new large-particle table","slug":"azd1981-new-large-particle-table","indication":"Other","status":"phase_1"},{"name":"AZD1981, new small-particle tablet","genericName":"AZD1981, new small-particle tablet","slug":"azd1981-new-small-particle-tablet","indication":"Other","status":"phase_1"},{"name":"AZD2275","genericName":"AZD2275","slug":"azd2275","indication":"Other","status":"phase_1"},{"name":"AZD2284","genericName":"AZD2284","slug":"azd2284","indication":"Other","status":"phase_1"},{"name":"AZD2327","genericName":"AZD2327","slug":"azd2327","indication":"Other","status":"phase_2"},{"name":"AZD2373 subcutaneous injection","genericName":"AZD2373 subcutaneous injection","slug":"azd2373-subcutaneous-injection","indication":"Other","status":"phase_1"},{"name":"AZD2624","genericName":"AZD2624","slug":"azd2624","indication":"Other","status":"phase_2"},{"name":"AZD2693","genericName":"AZD2693","slug":"azd2693","indication":"Other","status":"phase_2"},{"name":"AZD3199 Turbuhaler®","genericName":"AZD3199 Turbuhaler®","slug":"azd3199-turbuhaler","indication":"Other","status":"phase_1"},{"name":"AZD3241 ER formulation 1","genericName":"AZD3241 ER formulation 1","slug":"azd3241-er-formulation-1","indication":"Other","status":"phase_1"},{"name":"AZD3293","genericName":"AZD3293","slug":"azd3293","indication":"Other","status":"phase_1"},{"name":"AZD3470","genericName":"AZD3470","slug":"azd3470","indication":"Other","status":"phase_1"},{"name":"AZD4117","genericName":"AZD4117","slug":"azd4117","indication":"Other","status":"phase_1"},{"name":"AZD4144 Part A","genericName":"AZD4144 Part A","slug":"azd4144-part-a","indication":"Other","status":"phase_1"},{"name":"AZD4144 Part B","genericName":"AZD4144 Part B","slug":"azd4144-part-b","indication":"Other","status":"phase_1"},{"name":"AZD4248","genericName":"AZD4248","slug":"azd4248","indication":"Other","status":"phase_1"},{"name":"AZD4360","genericName":"AZD4360","slug":"azd4360","indication":"Other","status":"phase_1"},{"name":"AZD4451","genericName":"AZD4451","slug":"azd4451","indication":"Other","status":"phase_1"},{"name":"AZD4512","genericName":"AZD4512","slug":"azd4512","indication":"Other","status":"phase_1"},{"name":"AZD4604","genericName":"AZD4604","slug":"azd4604","indication":"Other","status":"phase_2"},{"name":"AZD4604 for IV administration","genericName":"AZD4604 for IV administration","slug":"azd4604-for-iv-administration","indication":"Other","status":"phase_1"},{"name":"AZD4604 for inhalation via DPI","genericName":"AZD4604 for inhalation via DPI","slug":"azd4604-for-inhalation-via-dpi","indication":"Other","status":"phase_1"},{"name":"AZD4604 for oral administration","genericName":"AZD4604 for oral administration","slug":"azd4604-for-oral-administration","indication":"Other","status":"phase_1"},{"name":"AZD4635 solid oral formulation - fasted","genericName":"AZD4635 solid oral formulation - fasted","slug":"azd4635-solid-oral-formulation-fasted","indication":"Other","status":"phase_1"},{"name":"AZD4635 solid oral formulation - fed","genericName":"AZD4635 solid oral formulation - fed","slug":"azd4635-solid-oral-formulation-fed","indication":"Other","status":"phase_1"},{"name":"AZD4721 Solution","genericName":"AZD4721 Solution","slug":"azd4721-solution","indication":"Other","status":"phase_1"},{"name":"AZD5004 film-coated tablet","genericName":"AZD5004 film-coated tablet","slug":"azd5004-film-coated-tablet","indication":"Other","status":"phase_1"},{"name":"AZD5055 film-coated tablet","genericName":"AZD5055 film-coated tablet","slug":"azd5055-film-coated-tablet","indication":"Other","status":"phase_1"},{"name":"AZD5122","genericName":"AZD5122","slug":"azd5122","indication":"Other","status":"phase_1"},{"name":"AZD5315","genericName":"AZD5315","slug":"azd5315","indication":"Other","status":"phase_1"},{"name":"AZD5438","genericName":"AZD5438","slug":"azd5438","indication":"Other","status":"phase_1"},{"name":"AZD5462 film-coated tablet","genericName":"AZD5462 film-coated tablet","slug":"azd5462-film-coated-tablet","indication":"Other","status":"phase_1"},{"name":"AZD5492","genericName":"AZD5492","slug":"azd5492","indication":"Other","status":"phase_1"},{"name":"AZD5634","genericName":"AZD5634","slug":"azd5634","indication":"Other","status":"phase_1"},{"name":"AZD5634 for infusion","genericName":"AZD5634 for infusion","slug":"azd5634-for-infusion","indication":"Other","status":"phase_1"},{"name":"AZD5634 for inhalation","genericName":"AZD5634 for inhalation","slug":"azd5634-for-inhalation","indication":"Other","status":"phase_1"},{"name":"AZD5718 IR tablet","genericName":"AZD5718 IR tablet","slug":"azd5718-ir-tablet","indication":"Other","status":"phase_1"},{"name":"AZD5718 tablet, Formulation B","genericName":"AZD5718 tablet, Formulation B","slug":"azd5718-tablet-formulation-b","indication":"Other","status":"phase_1"},{"name":"AZD5718 tablet, Formulation C","genericName":"AZD5718 tablet, Formulation C","slug":"azd5718-tablet-formulation-c","indication":"Other","status":"phase_1"},{"name":"AZD5863","genericName":"AZD5863","slug":"azd5863","indication":"Other","status":"phase_1"},{"name":"AZD6234 Formulation 1","genericName":"AZD6234 Formulation 1","slug":"azd6234-formulation-1","indication":"Other","status":"phase_1"},{"name":"AZD6234 Formulation 3","genericName":"AZD6234 Formulation 3","slug":"azd6234-formulation-3","indication":"Other","status":"phase_1"},{"name":"AZD6370","genericName":"AZD6370","slug":"azd6370","indication":"Other","status":"phase_1"},{"name":"AZD6750","genericName":"AZD6750","slug":"azd6750","indication":"Other","status":"phase_1"},{"name":"AZD7268","genericName":"AZD7268","slug":"azd7268","indication":"Other","status":"phase_2"},{"name":"AZD7503 Intervention","genericName":"AZD7503 Intervention","slug":"azd7503-intervention","indication":"Other","status":"phase_1"},{"name":"AZD7648","genericName":"AZD7648","slug":"azd7648","indication":"Other","status":"phase_1"},{"name":"AZD7789","genericName":"AZD7789","slug":"azd7789","indication":"Other","status":"phase_1"},{"name":"AZD8154","genericName":"AZD8154","slug":"azd8154","indication":"Other","status":"phase_1"},{"name":"AZD8205","genericName":"AZD8205","slug":"azd8205","indication":"Other","status":"phase_1"},{"name":"AZD8205 in combination with AZD9574","genericName":"AZD8205 in combination with AZD9574","slug":"azd8205-in-combination-with-azd9574","indication":"Other","status":"phase_1"},{"name":"AZD8233 subcutaneous injection","genericName":"AZD8233 subcutaneous injection","slug":"azd8233-subcutaneous-injection","indication":"Other","status":"phase_1"},{"name":"AZD8309","genericName":"AZD8309","slug":"azd8309","indication":"Other","status":"phase_1"},{"name":"AZD8329","genericName":"AZD8329","slug":"azd8329","indication":"Other","status":"phase_1"},{"name":"AZD8330","genericName":"AZD8330","slug":"azd8330","indication":"Other","status":"phase_1"},{"name":"AZD8566 IV carbon labelled","genericName":"AZD8566 IV carbon labelled","slug":"azd8566-iv-carbon-labelled","indication":"Other","status":"phase_1"},{"name":"AZD8630","genericName":"AZD8630","slug":"azd8630","indication":"Other","status":"phase_2"},{"name":"AZD8835","genericName":"AZD8835","slug":"azd8835","indication":"Other","status":"phase_1"},{"name":"AZD8871 100 µg","genericName":"AZD8871 100 µg","slug":"azd8871-100-g","indication":"Other","status":"phase_2"},{"name":"AZD8931","genericName":"AZD8931","slug":"azd8931","indication":"Advanced solid tumours","status":"phase_2"},{"name":"AZD9150, Durvalumab","genericName":"AZD9150, Durvalumab","slug":"azd9150-durvalumab","indication":"Other","status":"phase_1"},{"name":"AZD9291 tablets","genericName":"AZD9291 tablets","slug":"azd9291-tablets","indication":"Other","status":"phase_1"},{"name":"AZD9496 Variant A","genericName":"AZD9496 Variant A","slug":"azd9496-variant-a","indication":"Other","status":"phase_1"},{"name":"AZD9496 Variant D","genericName":"AZD9496 Variant D","slug":"azd9496-variant-d","indication":"Other","status":"phase_1"},{"name":"AZD9550 and AZD6234","genericName":"AZD9550 and AZD6234","slug":"azd9550-and-azd6234","indication":"Other","status":"phase_1"},{"name":"AZD9567 125 mg","genericName":"AZD9567 125 mg","slug":"azd9567-125-mg","indication":"Other","status":"phase_1"},{"name":"AZD9567 20 mg","genericName":"AZD9567 20 mg","slug":"azd9567-20-mg","indication":"Other","status":"phase_1"},{"name":"AZD9567 Monohydrat","genericName":"AZD9567 Monohydrat","slug":"azd9567-monohydrat","indication":"Other","status":"phase_1"},{"name":"AZD9742","genericName":"AZD9742","slug":"azd9742","indication":"Other","status":"phase_1"},{"name":"AZD9750","genericName":"AZD9750","slug":"azd9750","indication":"Other","status":"phase_1"},{"name":"AZD9819","genericName":"AZD9819","slug":"azd9819","indication":"Other","status":"phase_1"},{"name":"AZD9833 film-coated tablet A Dose 1","genericName":"AZD9833 film-coated tablet A Dose 1","slug":"azd9833-film-coated-tablet-a-dose-1","indication":"Other","status":"phase_1"},{"name":"AZD9833 film-coated tablet B Dose 1","genericName":"AZD9833 film-coated tablet B Dose 1","slug":"azd9833-film-coated-tablet-b-dose-1","indication":"Other","status":"phase_1"},{"name":"AZD9977, oral suspension","genericName":"AZD9977, oral suspension","slug":"azd9977-oral-suspension","indication":"Other","status":"phase_1"},{"name":"Aclidinium bromide and formoterol","genericName":"Aclidinium bromide and formoterol","slug":"aclidinium-bromide-and-formoterol","indication":"Other","status":"marketed"},{"name":"Administration of ceralasertib in combination with AZD5305","genericName":"Administration of ceralasertib in combination with AZD5305","slug":"administration-of-ceralasertib-in-combination-with-azd5305","indication":"Other","status":"phase_1"},{"name":"Albuterol and budesonide inhalation aerosol","genericName":"Albuterol and budesonide inhalation aerosol","slug":"albuterol-and-budesonide-inhalation-aerosol","indication":"Other","status":"marketed"},{"name":"Auto-injector with exenatide suspension","genericName":"Auto-injector with exenatide suspension","slug":"auto-injector-with-exenatide-suspension","indication":"Other","status":"phase_1"}]},{"name":"Immunology","slug":"immunology","revenue":3500000000,"percentOfTotal":9.1,"drugCount":7,"colorKey":"neuroscience","drugs":[{"name":"Pulmicort Respules","genericName":"BUDESONIDE","slug":"budesonide","indication":"Allergic Rhinitis Prevention","status":"marketed","revenue":2800000000},{"name":"Saphnelo","genericName":"ANIFROLUMAB","slug":"anifrolumab","indication":"Moderate to severe systemic lupus erythematosus (SLE)","status":"marketed","revenue":700000000},{"name":"AZD2927","genericName":"AZD2927","slug":"azd2927","indication":"Treatment of autoimmune diseases","status":"phase_2"},{"name":"AZD7442","genericName":"AZD7442","slug":"azd7442","indication":"Prevention of COVID-19 in adults and adolescents with inadequate immune response to vaccination","status":"phase_3"},{"name":"AZD8601","genericName":"AZD8601","slug":"azd8601","indication":"Treatment of rheumatoid arthritis","status":"phase_2"},{"name":"AZD9773","genericName":"AZD9773","slug":"azd9773","indication":"Systemic lupus erythematosus (SLE)","status":"phase_2"},{"name":"Budesonide 200 microgram","genericName":"Budesonide 200 microgram","slug":"budesonide-200-microgram","indication":"Maintenance treatment of asthma","status":"phase_2"}]},{"name":"Respiratory","slug":"respiratory","revenue":3400000000,"percentOfTotal":8.8,"drugCount":25,"colorKey":"infectious","drugs":[{"name":"Fasenra","genericName":"BENRALIZUMAB","slug":"benralizumab","indication":"Eosinophilic asthma","status":"marketed","revenue":1800000000},{"name":"Beyfortus","genericName":"NIRSEVIMAB","slug":"nirsevimab","indication":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","status":"marketed","revenue":800000000},{"name":"Tezspire","genericName":"AMG 157","slug":"amg-157","indication":"Severe asthma","status":"marketed","revenue":800000000},{"name":"Ciclesonide HFA","genericName":"Ciclesonide HFA","slug":"ciclesonide-hfa","indication":"Asthma","status":"phase_2"},{"name":"HFO-1234ze(E)","genericName":"HFO-1234ze(E)","slug":"hfo-1234ze-e","indication":"Propellant for metered-dose inhaler formulations in respiratory diseases (asthma, COPD, and other inhaled therapies)","status":"phase_3"},{"name":"Symbicort Turbuhaler 160/4.5","genericName":"Symbicort Turbuhaler 160/4.5","slug":"symbicort-turbuhaler-160-4-5","indication":"Asthma maintenance therapy","status":"marketed"},{"name":"Symbicort pMDI + budesonide HFA pMDI","genericName":"Symbicort pMDI + budesonide HFA pMDI","slug":"symbicort-pmdi-budesonide-hfa-pmdi","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Tezepelumab (AI)","genericName":"Tezepelumab (AI)","slug":"tezepelumab-ai","indication":"Severe asthma","status":"phase_3"},{"name":"albuterol (Ventolin)","genericName":"albuterol (Ventolin)","slug":"albuterol-ventolin","indication":"Maintenance and relief of bronchospasm in asthma and chronic obstructive pulmonary disease (COPD)","status":"phase_3"},{"name":"Aclidinium Bromide 200 µg","genericName":"Aclidinium Bromide 200 µg","slug":"aclidinium-bromide-200-g","indication":"Chronic obstructive pulmonary disease (COPD) maintenance treatment","status":"phase_3"},{"name":"Aclidinium Bromide 400 µg","genericName":"Aclidinium Bromide 400 µg","slug":"aclidinium-bromide-400-g","indication":"Chronic obstructive pulmonary disease (COPD) maintenance treatment","status":"phase_3"},{"name":"Aclidinium bromide/formoterol fumarate combination","genericName":"Aclidinium bromide/formoterol fumarate combination","slug":"aclidinium-bromide-formoterol-fumarate-combination","indication":"Chronic obstructive pulmonary disease (COPD) maintenance treatment","status":"marketed"},{"name":"Anoro® Ellipta®","genericName":"Anoro® Ellipta®","slug":"anoro-ellipta","indication":"Chronic obstructive pulmonary disease (COPD) maintenance treatment","status":"marketed"},{"name":"BEYFORTUS","genericName":"NIRSEVIMAB-ALIP","slug":"nirsevimab-alip","indication":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","status":"marketed"},{"name":"Benralizumab (Medi-563)","genericName":"Benralizumab (Medi-563)","slug":"benralizumab-medi-563","indication":"Moderate-to-severe eosinophilic asthma","status":"phase_3"},{"name":"Benralizumab Arm A","genericName":"Benralizumab Arm A","slug":"benralizumab-arm-a","indication":"Severe eosinophilic asthma","status":"phase_3"},{"name":"Benralizumab Arm B","genericName":"Benralizumab Arm B","slug":"benralizumab-arm-b","indication":"Moderate-to-severe eosinophilic asthma","status":"phase_3"},{"name":"Benralizumab Arm C","genericName":"Benralizumab Arm C","slug":"benralizumab-arm-c","indication":"Severe eosinophilic asthma","status":"phase_3"},{"name":"Biological: Experimental: Tezepelumab","genericName":"Biological: Experimental: Tezepelumab","slug":"biological-experimental-tezepelumab","indication":"Moderate-to-severe asthma (type 2 inflammation)","status":"phase_3"},{"name":"Budesonide CFC","genericName":"Budesonide CFC","slug":"budesonide-cfc","indication":"Asthma (maintenance and prevention)","status":"phase_3"},{"name":"Budesonide HFA","genericName":"Budesonide HFA","slug":"budesonide-hfa","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Budesonide HFA pMDI","genericName":"Budesonide HFA pMDI","slug":"budesonide-hfa-pmdi","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Budesonide Turbuhaler 200 µg","genericName":"Budesonide Turbuhaler 200 µg","slug":"budesonide-turbuhaler-200-g","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Budesonide inhalation suspension","genericName":"Budesonide inhalation suspension","slug":"budesonide-inhalation-suspension","indication":"Asthma maintenance therapy in children and adults","status":"marketed"},{"name":"Budesonide pMDI","genericName":"Budesonide pMDI","slug":"budesonide-pmdi","indication":"Asthma (maintenance and reliever therapy)","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":12,"colorKey":"respiratory","drugs":[{"name":"Koselugo","genericName":"selumetinib","slug":"selumetinib","indication":"Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas","status":"marketed"},{"name":"AZD6765 iv","genericName":"AZD6765 iv","slug":"azd6765-iv","indication":"Major depressive disorder (treatment-resistant depression)","status":"phase_2"},{"name":"Endep","genericName":"AMITRIPTYLINE","slug":"amitriptyline","indication":"Depressive disorder","status":"marketed"},{"name":"Seroquel IR - quetiapine fumarate","genericName":"Seroquel IR - quetiapine fumarate","slug":"seroquel-ir-quetiapine-fumarate","indication":"Schizophrenia","status":"marketed"},{"name":"Seroquel and Risperidone","genericName":"Seroquel and Risperidone","slug":"seroquel-and-risperidone","indication":"Schizophrenia","status":"marketed"},{"name":"Wainua","genericName":"EPLONTERSEN","slug":"eplontersen","indication":"Polyneuropathy of hereditary transthyretin-mediated amyloidosis","status":"marketed"},{"name":"Zomig","genericName":"ZOLMITRIPTAN","slug":"zolmitriptan","indication":"Acute treatment of migraine","status":"marketed"},{"name":"adequate mood stabilizer","genericName":"adequate mood stabilizer","slug":"adequate-mood-stabilizer","indication":"Bipolar disorder","status":"phase_3"},{"name":"divalproex (mood stabilizer)","genericName":"divalproex (mood stabilizer)","slug":"divalproex-mood-stabilizer","indication":"Mania associated with bipolar disorder","status":"phase_3"},{"name":"AZD0780","genericName":"AZD0780","slug":"azd0780","indication":"Acute seizures or seizure clusters","status":"phase_3"},{"name":"AZD2811","genericName":"AZD2811","slug":"azd2811","indication":"Relapsing forms of multiple sclerosis","status":"phase_2"},{"name":"AZD2936","genericName":"AZD2936","slug":"azd2936","indication":"Relapsing multiple sclerosis","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":12,"colorKey":"rare","drugs":[{"name":"Byetta","genericName":"EXENATIDE","slug":"exenatide","indication":"Type 2 Diabetes Mellitus Treatment Adjunct","status":"marketed"},{"name":"Saxagliptin plus metformin IR","genericName":"Saxagliptin plus metformin IR","slug":"saxagliptin-plus-metformin-ir","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Symlin","genericName":"PRAMLINTIDE","slug":"pramlintide","indication":"Type 1 Diabetes Mellitus Treatment Adjunct","status":"marketed"},{"name":"Byetta","genericName":"Byetta","slug":"byetta","indication":"Type 2 Diabetes Mellitus Treatment Adjunct","status":"marketed"},{"name":"DPP4 inhibitor","genericName":"DPP4 inhibitor","slug":"dpp4-inhibitor","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"Metformin (blinded)","genericName":"Metformin (blinded)","slug":"metformin-blinded","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"ABT-335","genericName":"ABT-335","slug":"abt-335","indication":"Dyslipidemia with low HDL cholesterol","status":"phase_3"},{"name":"ABT-335 plus rosuvastatin","genericName":"ABT-335 plus rosuvastatin","slug":"abt-335-plus-rosuvastatin","indication":"Dyslipidemia with elevated triglycerides and LDL cholesterol","status":"phase_3"},{"name":"AC2993","genericName":"AC2993","slug":"ac2993","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"AZD0585","genericName":"AZD0585","slug":"azd0585","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"AZD5213","genericName":"AZD5213","slug":"azd5213","indication":"Type 2 diabetes","status":"phase_2"},{"name":"AZD8871 600 µg","genericName":"AZD8871 600 µg","slug":"azd8871-600-g","indication":"Type 2 diabetes","status":"phase_2"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"ophthalmology","drugs":[{"name":"AZD8848","genericName":"AZD8848","slug":"azd8848","indication":"Moderate to severe atopic dermatitis","status":"phase_2"},{"name":"AZD2389","genericName":"AZD2389","slug":"azd2389","indication":"Moderate to severe atopic dermatitis","status":"phase_2"},{"name":"AZD7009, no generic name available","genericName":"AZD7009, no generic name available","slug":"azd7009-no-generic-name-available","indication":"Moderate to severe atopic dermatitis","status":"phase_2"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"metabolic","drugs":[{"name":"4F-PCC","genericName":"4F-PCC","slug":"4f-pcc","indication":"Treatment of pain","status":"phase_2"},{"name":"Dalgan","genericName":"DEZOCINE","slug":"dezocine","indication":"Pain","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"dermatology","drugs":[{"name":"AZD1419","genericName":"AZD1419","slug":"azd1419","indication":"Geographic atrophy secondary to age-related macular degeneration","status":"phase_2"}]}],"pipeline":[{"name":"Farxiga","genericName":"DAPAGLIFLOZIN","slug":"dapagliflozin","phase":"marketed","mechanism":"Farxiga works by blocking the SGLT2 protein in the kidneys, reducing glucose reabsorption and promoting its excretion in the urine.","indications":["Chronic heart failure","Chronic kidney disease","Diabetes mellitus type 1","Diabetes mellitus type 2"],"catalyst":""},{"name":"Tagrisso","genericName":"osimertinib","slug":"osimertinib","phase":"marketed","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR.","indications":["Adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations","Treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations","First-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations","First-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, in combination with pemetrexed and platinum-based chemotherapy","Treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy"],"catalyst":""},{"name":"Ultomiris","genericName":"RAVULIZUMAB","slug":"ravulizumab","phase":"marketed","mechanism":"Ultomiris blocks the action of Complement C5 to prevent inflammation and damage to red blood cells.","indications":["Atypical hemolytic uremic syndrome (aHUS)","Generalized myasthenia gravis","Myasthenia gravis","Paroxysmal nocturnal hemoglobinuria"],"catalyst":""},{"name":"Imfinzi","genericName":"durvalumab","slug":"durvalumab","phase":"marketed","mechanism":"Imfinzi works by blocking the PD-L1 protein, allowing the immune system to recognize and attack cancer cells.","indications":["Extensive stage primary small cell carcinoma of lung","Liver cell carcinoma","Metastatic carcinoma to biliary tract","Non-small cell lung cancer","Small cell carcinoma of lung"],"catalyst":""},{"name":"Calquence","genericName":"ACALABRUTINIB","slug":"acalabrutinib","phase":"marketed","mechanism":"Calquence works by blocking the activity of the BTK enzyme, which is essential for the activation and survival of B cells.","indications":["Chronic lymphocyticleukemia/small lymphocytic lymphoma","Mantle cell lymphoma"],"catalyst":""},{"name":"Pulmicort Respules","genericName":"BUDESONIDE","slug":"budesonide","phase":"marketed","mechanism":"Glucocorticoid receptor","indications":["Allergic Rhinitis Prevention","Allergic rhinitis","Asthma","Asthma management","Chronic Non-Allergic Rhinitis"],"catalyst":""},{"name":"Lynparza","genericName":"olaparib","slug":"olaparib","phase":"marketed","mechanism":"Lynparza blocks the repair of DNA damage in cancer cells by inhibiting the enzyme PARP.","indications":["BRCA mutation-positive and HER2-negative breast cancer","Epithelial tumor of ovary","Hormone refractory prostate cancer","Human epidermal growth factor 2 negative carcinoma of breast","Malignant tumor of ovary"],"catalyst":""},{"name":"Fasenra","genericName":"BENRALIZUMAB","slug":"benralizumab","phase":"marketed","mechanism":"Fasenra works by binding to the interleukin-5 receptor on eosinophils, triggering their destruction.","indications":["Eosinophilic asthma"],"catalyst":""},{"name":"Opsumit","genericName":"MACITENTAN","slug":"macitentan","phase":"marketed","mechanism":"Opsumit works by blocking the action of endothelin-1, a protein that causes blood vessels to constrict and increase blood pressure.","indications":["Pulmonary arterial hypertension"],"catalyst":""},{"name":"Brilinta","genericName":"ticagrelor","slug":"ticagrelor","phase":"marketed","mechanism":"Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12","indications":["Acute coronary syndrome","Myocardial Reinfarction Prevention","Percutaneous coronary intervention","Peripheral vascular disease"],"catalyst":""},{"name":"Prilosec","genericName":"omeprazole","slug":"omeprazole","phase":"marketed","mechanism":"Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) in gastric parietal cells, potently suppressing stomach acid secretion.","indications":["Duodenal Ulcer due to H. Pylori","Duodenal ulcer disease","Erosive esophagitis","Gastric Hypersecretory Conditions","Gastric ulcer"],"catalyst":""},{"name":"Beyfortus","genericName":"NIRSEVIMAB","slug":"nirsevimab","phase":"marketed","mechanism":"BEYFORTUS is a monoclonal antibody that targets RSV.","indications":["Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease"],"catalyst":""},{"name":"Tezspire","genericName":"AMG 157","slug":"amg-157","phase":"marketed","mechanism":"Tezspire blocks the action of Thymic Stromal Lymphopoietin (TSLP), a protein that triggers inflammation in the airways.","indications":["Severe asthma"],"catalyst":""},{"name":"Saphnelo","genericName":"ANIFROLUMAB","slug":"anifrolumab","phase":"marketed","mechanism":"Saphnelo blocks the action of interferon alpha/beta, a protein that triggers an immune response.","indications":["Moderate to severe systemic lupus erythematosus (SLE)"],"catalyst":""},{"name":"Imjudo","genericName":"TREMELIMUMAB","slug":"tremelimumab","phase":"marketed","mechanism":"Tremelimumab-actl binds to CTLA-4, blocking its interaction with CD80 and CD86, thereby enhancing T-cell activation and reducing tumor growth.","indications":["Liver cell carcinoma","Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations","Non-small cell lung cancer, negative for epidermal growth factor receptor expression"],"catalyst":""},{"name":"Lumoxiti","genericName":"MOXETUMOMAB PASUDOTOX","slug":"moxetumomab-pasudotox","phase":"marketed","mechanism":"B-cell receptor CD22","indications":["Hairy cell leukemia"],"catalyst":""},{"name":"Crestor","genericName":"rosuvastatin","slug":"rosuvastatin","phase":"marketed","mechanism":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor.","indications":["Arteriosclerotic vascular disease","Cerebrovascular accident","Familial hypercholesterolemia - heterozygous","Familial hypercholesterolemia - homozygous","Familial type 3 hyperlipoproteinemia"],"catalyst":""},{"name":"Arimidex","genericName":"anastrozole","slug":"anastrozole","phase":"marketed","mechanism":"Anastrozole selectively inhibits aromatase enzyme, suppressing estrogen biosynthesis in postmenopausal breast cancer.","indications":["Adjuvant treatment of early breast cancer","First-line treatment of advanced breast cancer","Second-line treatment of advanced breast cancer"],"catalyst":""},{"name":"Faslodex","genericName":"fulvestrant","slug":"fulvestrant","phase":"marketed","mechanism":"Faslodex works by binding to and degrading the estrogen receptor, preventing it from promoting the growth of cancer cells.","indications":["Metastatic Breast Cancer Progression Post-Antiestrogen Therapy"],"catalyst":""},{"name":"Koselugo","genericName":"selumetinib","slug":"selumetinib","phase":"marketed","mechanism":"Selumetinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2).","indications":["Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas"],"catalyst":""},{"name":"Nolvadex","genericName":"tamoxifen","slug":"tamoxifen","phase":"marketed","mechanism":"Selective estrogen receptor modulator (SERM) that blocks estrogen signaling in breast tissue while preserving bone density.","indications":["Carcinoma of female breast","Infiltrating duct carcinoma of breast","Prevention of Breast Carcinoma"],"catalyst":""},{"name":"Byetta","genericName":"EXENATIDE","slug":"exenatide","phase":"marketed","mechanism":"Byetta works by mimicking the action of a natural hormone in the body to regulate blood sugar levels.","indications":["Type 2 Diabetes Mellitus Treatment Adjunct"],"catalyst":""},{"name":"Saxagliptin plus metformin IR","genericName":"Saxagliptin plus metformin IR","slug":"saxagliptin-plus-metformin-ir","phase":"phase_3","mechanism":"Saxagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and lower blood glucose, while metformin reduces hepatic glucose production and improves insulin sensitivity.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Symlin","genericName":"PRAMLINTIDE","slug":"pramlintide","phase":"marketed","mechanism":"Amylin receptor AMY2, Amylin receptor AMY1, Amylin receptor AMY3","indications":["Type 1 Diabetes Mellitus Treatment Adjunct","Type 2 Diabetes Mellitus Treatment Adjunct"],"catalyst":""},{"name":"Uptravi","genericName":"SELEXIPAG","slug":"selexipag","phase":"marketed","mechanism":"Uptravi works by activating the prostacyclin receptor, which helps to relax blood vessels and improve blood flow.","indications":["Pulmonary arterial hypertension","Thromboembolic pulmonary hypertension"],"catalyst":""},{"name":"arimidex dummy","genericName":"arimidex dummy","slug":"arimidex-dummy","phase":"phase_3","mechanism":"Arimidex is an aromatase inhibitor that blocks the enzyme responsible for converting androgens to estrogens.","indications":["Treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy","Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women following surgery"],"catalyst":""},{"name":"4F-PCC","genericName":"4F-PCC","slug":"4f-pcc","phase":"phase_2","mechanism":"4F-PCC is a synthetic cannabinoid receptor agonist.","indications":["Treatment of pain"],"catalyst":""},{"name":"AC2307","genericName":"AC2307","slug":"ac2307","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AC2592","genericName":"AC2592","slug":"ac2592","phase":"phase_2","mechanism":"AC2592 is a small molecule inhibitor of the PI3K delta subunit.","indications":["Treatment of relapsed or refractory follicular lymphoma"],"catalyst":""},{"name":"AZD 1775","genericName":"AZD 1775","slug":"azd-1775","phase":"phase_1","mechanism":"AZD1775 is a selective inhibitor of the Wee1 kinase, which plays a critical role in cell cycle regulation and DNA damage response.","indications":["Advanced solid tumors"],"catalyst":""},{"name":"AZD 8529","genericName":"AZD 8529","slug":"azd-8529","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD0120","genericName":"AZD0120","slug":"azd0120","phase":"phase_3","mechanism":"AZD0120 is a selective inhibitor of fibroblast growth factor receptor 1 (FGFR1) that blocks aberrant signaling in cancer cells dependent on FGFR1 activation.","indications":["FGFR1-amplified or FGFR1-altered solid tumors"],"catalyst":""},{"name":"AZD0156","genericName":"AZD0156","slug":"azd0156","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD0305","genericName":"AZD0305","slug":"azd0305","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD0486 IV","genericName":"AZD0486 IV","slug":"azd0486-iv","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD0516","genericName":"AZD0516","slug":"azd0516","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD1163","genericName":"AZD1163","slug":"azd1163","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AZD1613","genericName":"AZD1613","slug":"azd1613","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD2287","genericName":"AZD2287","slug":"azd2287","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AZD2927","genericName":"AZD2927","slug":"azd2927","phase":"phase_2","mechanism":"AZD2927 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","indications":["Treatment of autoimmune diseases"],"catalyst":""},{"name":"AZD2962","genericName":"AZD2962","slug":"azd2962","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD3241","genericName":"AZD3241","slug":"azd3241","phase":"phase_2","mechanism":"AZD3241 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","indications":["Relapsed or refractory chronic lymphocytic leukemia (CLL)"],"catalyst":""},{"name":"AZD3293 tablet formulation A","genericName":"AZD3293 tablet formulation A","slug":"azd3293-tablet-formulation-a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD3293 tablet formulation B","genericName":"AZD3293 tablet formulation B","slug":"azd3293-tablet-formulation-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD3355","genericName":"AZD3355","slug":"azd3355","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD3632","genericName":"AZD3632","slug":"azd3632","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD3839","genericName":"AZD3839","slug":"azd3839","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD3974","genericName":"AZD3974","slug":"azd3974","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD4017","genericName":"AZD4017","slug":"azd4017","phase":"phase_2","mechanism":"AZD4017 is a small molecule inhibitor of the sodium-hydrogen exchanger 1 (NHE1).","indications":["Atrial fibrillation for stroke prevention"],"catalyst":""},{"name":"AZD4063","genericName":"AZD4063","slug":"azd4063","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD4076","genericName":"AZD4076","slug":"azd4076","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD4144","genericName":"AZD4144","slug":"azd4144","phase":"phase_2","mechanism":"AZD4144 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","indications":["Relapsed or refractory chronic lymphocytic leukemia (CLL)"],"catalyst":""},{"name":"AZD4573","genericName":"AZD4573","slug":"azd4573","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD4635","genericName":"AZD4635","slug":"azd4635","phase":"phase_2","mechanism":"AZD4635 is a small molecule inhibitor of the adenosine A2A receptor.","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"AZD4785","genericName":"AZD4785","slug":"azd4785","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD4916","genericName":"AZD4916","slug":"azd4916","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD4954","genericName":"AZD4954","slug":"azd4954","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD4956","genericName":"AZD4956","slug":"azd4956","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD5055 solution for infusion","genericName":"AZD5055 solution for infusion","slug":"azd5055-solution-for-infusion","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD5312","genericName":"AZD5312","slug":"azd5312","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD5423","genericName":"AZD5423","slug":"azd5423","phase":"phase_2","mechanism":"AZD5423 is a small molecule inhibitor of the CD73 enzyme.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"AZD5658","genericName":"AZD5658","slug":"azd5658","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD6140","genericName":"AZD6140","slug":"azd6140","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD6234","genericName":"AZD6234","slug":"azd6234","phase":"phase_2","mechanism":"AZD6234 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","indications":["Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)","Relapsed or refractory follicular lymphoma"],"catalyst":""},{"name":"AZD6482","genericName":"AZD6482","slug":"azd6482","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD6563","genericName":"AZD6563","slug":"azd6563","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AZD6621","genericName":"AZD6621","slug":"azd6621","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD6765 iv","genericName":"AZD6765 iv","slug":"azd6765-iv","phase":"phase_2","mechanism":"AZD6765 is an NMDA receptor antagonist that modulates glutamatergic neurotransmission to produce rapid-acting antidepressant effects.","indications":["Major depressive disorder (treatment-resistant depression)"],"catalyst":""},{"name":"AZD6793","genericName":"AZD6793","slug":"azd6793","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD7053","genericName":"AZD7053","slug":"azd7053","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD7295","genericName":"AZD7295","slug":"azd7295","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD7442","genericName":"AZD7442","slug":"azd7442","phase":"phase_3","mechanism":"AZD7442 is a combination of two monoclonal antibodies that bind to the SARS-CoV-2 spike protein to neutralize the virus and provide passive immunity.","indications":["Prevention of COVID-19 in adults and adolescents with inadequate immune response to vaccination","Treatment of mild-to-moderate COVID-19 in high-risk patients"],"catalyst":""},{"name":"AZD7687","genericName":"AZD7687","slug":"azd7687","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD7760","genericName":"AZD7760","slug":"azd7760","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD7798","genericName":"AZD7798","slug":"azd7798","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD7986","genericName":"AZD7986","slug":"azd7986","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD8421","genericName":"AZD8421","slug":"azd8421","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD8566","genericName":"AZD8566","slug":"azd8566","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD8601","genericName":"AZD8601","slug":"azd8601","phase":"phase_2","mechanism":"AZD8601 is a selective and potent inhibitor of the PI3K gamma isoform.","indications":["Treatment of rheumatoid arthritis"],"catalyst":""},{"name":"AZD8701","genericName":"AZD8701","slug":"azd8701","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD8848","genericName":"AZD8848","slug":"azd8848","phase":"phase_2","mechanism":"AZD8848 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","indications":["Moderate to severe atopic dermatitis"],"catalyst":""},{"name":"AZD9291 Dosing","genericName":"AZD9291 Dosing","slug":"azd9291-dosing","phase":"phase_3","mechanism":"AZD9291 is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations, while sparing wild-type EGFR.","indications":["Non-small cell lung cancer with EGFR T790M mutation after progression on first- or second-generation EGFR inhibitors","EGFR-mutant non-small cell lung cancer (first-line treatment)"],"catalyst":""},{"name":"AZD9496","genericName":"AZD9496","slug":"azd9496","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD9496 Variant B","genericName":"AZD9496 Variant B","slug":"azd9496-variant-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD9567","genericName":"AZD9567","slug":"azd9567","phase":"phase_2","mechanism":"AZD9567 is a small molecule that inhibits the activity of the PI3K delta subunit.","indications":["Relapsed or refractory chronic lymphocytic leukemia (CLL)"],"catalyst":""},{"name":"AZD9574","genericName":"AZD9574","slug":"azd9574","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD9829","genericName":"AZD9829","slug":"azd9829","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD9838","genericName":"AZD9838","slug":"azd9838","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"BMS-512148","genericName":"BMS-512148","slug":"bms-512148","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Byetta","genericName":"Byetta","slug":"byetta","phase":"marketed","mechanism":"Byetta works by activating the glucagon-like peptide 1 receptor, which helps regulate blood sugar levels.","indications":["Type 2 Diabetes Mellitus Treatment Adjunct"],"catalyst":""},{"name":"Ciclesonide HFA","genericName":"Ciclesonide HFA","slug":"ciclesonide-hfa","phase":"phase_2","mechanism":"Ciclesonide is a prodrug that is converted to its active metabolite, des-ciclesonide, which binds to glucocorticoid receptors in the cytoplasm, leading to anti-inflammatory effects.","indications":["Asthma"],"catalyst":""},{"name":"DPP4 inhibitor","genericName":"DPP4 inhibitor","slug":"dpp4-inhibitor","phase":"marketed","mechanism":"DPP4 inhibitors block the enzyme dipeptidyl peptidase-4, which prolongs the activity of incretin hormones that stimulate insulin secretion in response to glucose.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Dalgan","genericName":"DEZOCINE","slug":"dezocine","phase":"marketed","mechanism":"Mu-type opioid receptor","indications":["Pain"],"catalyst":""},{"name":"Dato-DXd","genericName":"Dato-DXd","slug":"dato-dxd","phase":"phase_3","mechanism":"Dato-DXd is an antibody-drug conjugate that targets TROP-2 on cancer cells and delivers a DNA-damaging payload (deruxtecan) to induce cell death.","indications":["Metastatic or unresectable gastric cancer","Metastatic or unresectable biliary tract cancer","Non-small cell lung cancer (NSCLC)"],"catalyst":""},{"name":"Endep","genericName":"AMITRIPTYLINE","slug":"amitriptyline","phase":"marketed","mechanism":"Histamine H1 receptor","indications":["Depressive disorder","Mixed anxiety and depressive disorder"],"catalyst":""},{"name":"HFA MDI","genericName":"HFA MDI","slug":"hfa-mdi","phase":"phase_3","mechanism":"HFA MDI is a hydrofluoroalkane-based metered-dose inhaler formulation that delivers aerosolized medication directly to the respiratory tract.","indications":[],"catalyst":""},{"name":"HFA-134a","genericName":"HFA-134a","slug":"hfa-134a","phase":"phase_3","mechanism":"HFA-134a is a hydrofluoroalkane propellant used in pressurized metered-dose inhalers (pMDIs) to deliver aerosolized medications to the lungs.","indications":["Propellant for pressurized metered-dose inhalers delivering bronchodilators, corticosteroids, and other inhaled medications"],"catalyst":""},{"name":"HFO-1234ze(E)","genericName":"HFO-1234ze(E)","slug":"hfo-1234ze-e","phase":"phase_3","mechanism":"HFO-1234ze(E) is a hydrofluoroolefin (HFO) propellant used in metered-dose inhalers as a replacement for chlorofluorocarbon (CFC) and hydrochlorofluoroalkane (HCFA) propellants.","indications":["Propellant for metered-dose inhaler formulations in respiratory diseases (asthma, COPD, and other inhaled therapies)"],"catalyst":""},{"name":"MEDI-545 600","genericName":"MEDI-545 600","slug":"medi-545-600","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MITT","genericName":"MITT","slug":"mitt","phase":"marketed","mechanism":"MITT is a mitochondrial-targeted therapeutic that enhances mitochondrial function and cellular energy production.","indications":[],"catalyst":""},{"name":"Metformin (blinded)","genericName":"Metformin (blinded)","slug":"metformin-blinded","phase":"phase_3","mechanism":"Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK).","indications":["Type 2 diabetes mellitus","Prediabetes (prevention of progression to type 2 diabetes)","Polycystic ovary syndrome (PCOS)"],"catalyst":""},{"name":"NXY-059","genericName":"NXY-059","slug":"nxy-059","phase":"phase_3","mechanism":"NXY-059 is a free radical-trapping agent that scavenges harmful free radicals produced during ischemic stroke to reduce neuronal damage.","indications":["Acute ischemic stroke (within 6 hours of symptom onset)"],"catalyst":""},{"name":"Plendil","genericName":"FELODIPINE","slug":"felodipine","phase":"marketed","mechanism":"Plendil works by blocking calcium channels in blood vessel walls, causing them to relax and widen, which lowers blood pressure.","indications":["Hypertensive disorder"],"catalyst":""},{"name":"Proventil 180 μg","genericName":"Proventil 180 μg","slug":"proventil-180-g","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Rosuvastatin; improvement of lipid profile","genericName":"Rosuvastatin; improvement of lipid profile","slug":"rosuvastatin-improvement-of-lipid-profile","phase":"marketed","mechanism":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol and triglycerides while raising HDL cholesterol.","indications":["Hypercholesterolemia and mixed dyslipidemia","Primary prevention of cardiovascular disease in at-risk patients","Secondary prevention of cardiovascular events in patients with established coronary heart disease"],"catalyst":""},{"name":"Seasonal influenza virus vaccine","genericName":"Seasonal influenza virus vaccine","slug":"seasonal-influenza-virus-vaccine","phase":"phase_3","mechanism":"This vaccine induces an immune response against seasonal influenza viruses.","indications":["Prevention of seasonal influenza disease"],"catalyst":""},{"name":"Seroquel IR - quetiapine fumarate","genericName":"Seroquel IR - quetiapine fumarate","slug":"seroquel-ir-quetiapine-fumarate","phase":"marketed","mechanism":"Quetiapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.","indications":["Schizophrenia","Bipolar I disorder (acute manic and depressive episodes)","Major depressive disorder (as adjunctive therapy)","Generalized anxiety disorder"],"catalyst":""},{"name":"Seroquel and Risperidone","genericName":"Seroquel and Risperidone","slug":"seroquel-and-risperidone","phase":"marketed","mechanism":"Both drugs are atypical antipsychotics that block dopamine D2 receptors and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","indications":["Schizophrenia","Bipolar I disorder (acute mania and maintenance)","Irritability associated with autism spectrum disorder (risperidone)","Major depressive disorder (adjunctive, quetiapine)"],"catalyst":""},{"name":"Symbicort","genericName":"Symbicort","slug":"symbicort","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Symbicort Turbuhaler 160/4.5","genericName":"Symbicort Turbuhaler 160/4.5","slug":"symbicort-turbuhaler-160-4-5","phase":"marketed","mechanism":"Symbicort combines a long-acting beta-2 agonist (formoterol) and an inhaled corticosteroid (budesonide) to reduce airway inflammation and improve bronchial smooth muscle relaxation.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Symbicort pMDI + budesonide HFA pMDI","genericName":"Symbicort pMDI + budesonide HFA pMDI","slug":"symbicort-pmdi-budesonide-hfa-pmdi","phase":"phase_3","mechanism":"Budesonide is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Tamoxifen (Nolvadex)","genericName":"Tamoxifen (Nolvadex)","slug":"tamoxifen-nolvadex","phase":"phase_3","mechanism":"Tamoxifen acts as a selective estrogen receptor modulator (SERM) to inhibit estrogen's action on breast cancer cells.","indications":["Adjuvant treatment of breast cancer in postmenopausal women with estrogen receptor-positive disease","Treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive disease"],"catalyst":""},{"name":"Tezepelumab (AI)","genericName":"Tezepelumab (AI)","slug":"tezepelumab-ai","phase":"phase_3","mechanism":"Tezepelumab is an interleukin-33 (IL-33) antagonist that blocks the activity of IL-33, a cytokine involved in the development of asthma.","indications":["Severe asthma"],"catalyst":""},{"name":"Tremelimumab (Regimen 2)","genericName":"Tremelimumab (Regimen 2)","slug":"tremelimumab-regimen-2","phase":"phase_3","mechanism":"Tremelimumab is a monoclonal antibody that blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.","indications":["Unresectable or metastatic melanoma (in combination with durvalumab)","Hepatocellular carcinoma (in combination with durvalumab)"],"catalyst":""},{"name":"Wainua","genericName":"EPLONTERSEN","slug":"eplontersen","phase":"marketed","mechanism":"Wainua works by binding to the transthyretin RNA to prevent the production of the transthyretin protein.","indications":["Polyneuropathy of hereditary transthyretin-mediated amyloidosis"],"catalyst":""},{"name":"Zomig","genericName":"ZOLMITRIPTAN","slug":"zolmitriptan","phase":"marketed","mechanism":"Zolmitriptan works by binding to serotonin receptors in the brain to constrict blood vessels and block pain pathways.","indications":["Acute treatment of migraine"],"catalyst":""},{"name":"adequate mood stabilizer","genericName":"adequate mood stabilizer","slug":"adequate-mood-stabilizer","phase":"phase_3","mechanism":"This drug stabilizes mood by modulating neurotransmitter activity.","indications":["Bipolar disorder","Major depressive disorder"],"catalyst":""},{"name":"albuterol (Ventolin)","genericName":"albuterol (Ventolin)","slug":"albuterol-ventolin","phase":"phase_3","mechanism":"Albuterol is a beta-2 adrenergic receptor agonist that works by relaxing bronchial muscles and increasing air flow to the lungs.","indications":["Maintenance and relief of bronchospasm in asthma and chronic obstructive pulmonary disease (COPD)","Prevention of bronchospasm during exercise"],"catalyst":""},{"name":"divalproex (mood stabilizer)","genericName":"divalproex (mood stabilizer)","slug":"divalproex-mood-stabilizer","phase":"phase_3","mechanism":"Divalproex works by stabilizing mood by modulating the activity of neurotransmitters in the brain.","indications":["Mania associated with bipolar disorder","Seizure disorders"],"catalyst":""},{"name":"pegfiligrastim","genericName":"pegfiligrastim","slug":"pegfiligrastim","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"5-flourouracil","genericName":"5-flourouracil","slug":"5-flourouracil","phase":"phase_2","mechanism":"5-fluorouracil is a thymidylate synthase inhibitor that disrupts DNA synthesis in rapidly dividing cancer cells.","indications":["Adjuvant treatment of colon cancer","Treatment of breast cancer","Treatment of stomach cancer"],"catalyst":""},{"name":"ABT-143","genericName":"ABT-143","slug":"abt-143","phase":"phase_3","mechanism":"ABT-143 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"ABT-335","genericName":"ABT-335","slug":"abt-335","phase":"phase_3","mechanism":"ABT-335 is a selective peroxisome proliferator-activated receptor delta (PPARδ) agonist that modulates lipid and glucose metabolism.","indications":["Dyslipidemia with low HDL cholesterol","Hypertriglyceridemia"],"catalyst":""},{"name":"ABT-335 and rosuvastatin calcium","genericName":"ABT-335 and rosuvastatin calcium","slug":"abt-335-and-rosuvastatin-calcium","phase":"phase_3","mechanism":"ABT-335 (fenofibrate) reduces triglycerides and raises HDL cholesterol by activating peroxisome proliferator-activated receptor alpha (PPARα), while rosuvastatin calcium lowers LDL cholesterol by inhibiting HMG-CoA reductase.","indications":["Dyslipidemia with elevated triglycerides and low HDL cholesterol","Cardiovascular risk reduction in patients with mixed dyslipidemia"],"catalyst":""},{"name":"ABT-335 plus rosuvastatin","genericName":"ABT-335 plus rosuvastatin","slug":"abt-335-plus-rosuvastatin","phase":"phase_3","mechanism":"ABT-335 (fenofibrate analog) combined with rosuvastatin reduces triglycerides and LDL cholesterol through dual lipid-lowering pathways.","indications":["Dyslipidemia with elevated triglycerides and LDL cholesterol"],"catalyst":""},{"name":"AC2993","genericName":"AC2993","slug":"ac2993","phase":"phase_3","mechanism":"AC2993 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"ACS patients treated with OAP","genericName":"ACS patients treated with OAP","slug":"acs-patients-treated-with-oap","phase":"phase_2","mechanism":"OAP is an angiotensin receptor-neprilysin inhibitor.","indications":["Treatment of heart failure"],"catalyst":""},{"name":"AMG 139","genericName":"AMG 139","slug":"amg-139","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AR-C165395XX","genericName":"AR-C165395XX","slug":"ar-c165395xx","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ARIMIDEX (anastrazole)","genericName":"ARIMIDEX (anastrazole)","slug":"arimidex-anastrazole","phase":"phase_3","mechanism":"Anastrozole is a non-steroidal aromatase inhibitor that blocks the conversion of androgens to estrogen in postmenopausal women.","indications":["Hormone receptor-positive early-stage breast cancer in postmenopausal women (adjuvant therapy)","Metastatic hormone receptor-positive breast cancer in postmenopausal women","Extended adjuvant therapy following tamoxifen in postmenopausal women with early-stage breast cancer"],"catalyst":""},{"name":"AS MDI","genericName":"AS MDI","slug":"as-mdi","phase":"phase_3","mechanism":"AS MDI is a metered-dose inhaler formulation that delivers an active pharmaceutical agent directly to the respiratory tract for local and/or systemic therapeutic effect.","indications":[],"catalyst":""},{"name":"AS MDI 180 µg","genericName":"AS MDI 180 µg","slug":"as-mdi-180-g","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD0120 - Regimen 1","genericName":"AZD0120 - Regimen 1","slug":"azd0120-regimen-1","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AZD0120 - Regimen 2","genericName":"AZD0120 - Regimen 2","slug":"azd0120-regimen-2","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AZD0171","genericName":"AZD0171","slug":"azd0171","phase":"phase_2","mechanism":"AZD0171 is a small molecule inhibitor of the PI3K delta subunit.","indications":["Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)","Relapsed or refractory follicular lymphoma"],"catalyst":""},{"name":"AZD0284","genericName":"AZD0284","slug":"azd0284","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD0292","genericName":"AZD0292","slug":"azd0292","phase":"phase_2","mechanism":"AZD0292 is a small molecule inhibitor of the PI3K delta subunit.","indications":["Relapsed or refractory chronic lymphocytic leukemia","Relapsed or refractory non-Hodgkin lymphoma"],"catalyst":""},{"name":"AZD0449","genericName":"AZD0449","slug":"azd0449","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD0486","genericName":"AZD0486","slug":"azd0486","phase":"phase_3","mechanism":"AZD0486 is a selective inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1) that suppresses protein synthesis and cell proliferation in cancer cells.","indications":["Advanced or metastatic solid tumors with mTOR pathway activation"],"catalyst":""},{"name":"AZD0585","genericName":"AZD0585","slug":"azd0585","phase":"phase_3","mechanism":"AZD0585 is a selective activator of the glucokinase enzyme that enhances glucose sensing and insulin secretion in pancreatic beta cells.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"AZD0754","genericName":"AZD0754","slug":"azd0754","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AZD0780","genericName":"AZD0780","slug":"azd0780","phase":"phase_3","mechanism":"AZD0780 is a selective GABA-A receptor positive allosteric modulator that enhances inhibitory neurotransmission in the central nervous system.","indications":["Acute seizures or seizure clusters","Status epilepticus (investigational)"],"catalyst":""},{"name":"AZD0837","genericName":"AZD0837","slug":"azd0837","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD0865","genericName":"AZD0865","slug":"azd0865","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD0901","genericName":"AZD0901","slug":"azd0901","phase":"phase_3","mechanism":"AZD0901 is a selective activator of the soluble guanylate cyclase (sGC) enzyme that increases intracellular cGMP levels to promote vasodilation and reduce fibrosis.","indications":["Pulmonary hypertension","Heart failure with preserved ejection fraction (HFpEF)"],"catalyst":""},{"name":"AZD1152 part A","genericName":"AZD1152 part A","slug":"azd1152-part-a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD1152 part B","genericName":"AZD1152 part B","slug":"azd1152-part-b","phase":"phase_1","mechanism":"AZD1152 is a selective Aurora B kinase inhibitor that disrupts mitotic progression and leads to cell cycle arrest and apoptosis in cancer cells.","indications":["Solid tumors"],"catalyst":""},{"name":"AZD1419","genericName":"AZD1419","slug":"azd1419","phase":"phase_2","mechanism":"AZD1419 is a recombinant human angiopoietin-2 (Ang-2) decoy receptor.","indications":["Geographic atrophy secondary to age-related macular degeneration"],"catalyst":""},{"name":"AZD1613 - Part A","genericName":"AZD1613 - Part A","slug":"azd1613-part-a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD1613 - Part B","genericName":"AZD1613 - Part B","slug":"azd1613-part-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD1656","genericName":"AZD1656","slug":"azd1656","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD1705","genericName":"AZD1705","slug":"azd1705","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD1940","genericName":"AZD1940","slug":"azd1940","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD1981, current small-particle tablet","genericName":"AZD1981, current small-particle tablet","slug":"azd1981-current-small-particle-tablet","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD1981, new large-particle table","genericName":"AZD1981, new large-particle table","slug":"azd1981-new-large-particle-table","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD1981, new small-particle tablet","genericName":"AZD1981, new small-particle tablet","slug":"azd1981-new-small-particle-tablet","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD2275","genericName":"AZD2275","slug":"azd2275","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD2281","genericName":"AZD2281","slug":"azd2281","phase":"phase_2","mechanism":"PARP inhibitor","indications":["Ovarian cancer","Breast cancer"],"catalyst":""},{"name":"AZD2284","genericName":"AZD2284","slug":"azd2284","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD2327","genericName":"AZD2327","slug":"azd2327","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD2373 subcutaneous injection","genericName":"AZD2373 subcutaneous injection","slug":"azd2373-subcutaneous-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD2389","genericName":"AZD2389","slug":"azd2389","phase":"phase_2","mechanism":"AZD2389 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","indications":["Moderate to severe atopic dermatitis"],"catalyst":""},{"name":"AZD2624","genericName":"AZD2624","slug":"azd2624","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD2693","genericName":"AZD2693","slug":"azd2693","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD2811","genericName":"AZD2811","slug":"azd2811","phase":"phase_2","mechanism":"AZD2811 is a small molecule that targets the S1P1 receptor.","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""},{"name":"AZD2816","genericName":"AZD2816","slug":"azd2816","phase":"phase_2","mechanism":"AZD2816 is a small molecule inhibitor of the PI3K delta subunit.","indications":["Relapsed or refractory chronic lymphocytic leukemia (CLL)"],"catalyst":""},{"name":"AZD2936","genericName":"AZD2936","slug":"azd2936","phase":"phase_2","mechanism":"AZD2936 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","indications":["Relapsing multiple sclerosis"],"catalyst":""},{"name":"AZD3199 Turbuhaler®","genericName":"AZD3199 Turbuhaler®","slug":"azd3199-turbuhaler","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD3241 ER formulation 1","genericName":"AZD3241 ER formulation 1","slug":"azd3241-er-formulation-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD3293","genericName":"AZD3293","slug":"azd3293","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD3470","genericName":"AZD3470","slug":"azd3470","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD4117","genericName":"AZD4117","slug":"azd4117","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AZD4144 Part A","genericName":"AZD4144 Part A","slug":"azd4144-part-a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD4144 Part B","genericName":"AZD4144 Part B","slug":"azd4144-part-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD4248","genericName":"AZD4248","slug":"azd4248","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD4360","genericName":"AZD4360","slug":"azd4360","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD4451","genericName":"AZD4451","slug":"azd4451","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD4512","genericName":"AZD4512","slug":"azd4512","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD4604","genericName":"AZD4604","slug":"azd4604","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD4604 for IV administration","genericName":"AZD4604 for IV administration","slug":"azd4604-for-iv-administration","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD4604 for inhalation via DPI","genericName":"AZD4604 for inhalation via DPI","slug":"azd4604-for-inhalation-via-dpi","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD4604 for oral administration","genericName":"AZD4604 for oral administration","slug":"azd4604-for-oral-administration","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD4635 solid oral formulation - fasted","genericName":"AZD4635 solid oral formulation - fasted","slug":"azd4635-solid-oral-formulation-fasted","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD4635 solid oral formulation - fed","genericName":"AZD4635 solid oral formulation - fed","slug":"azd4635-solid-oral-formulation-fed","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD4721 Solution","genericName":"AZD4721 Solution","slug":"azd4721-solution","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD5004","genericName":"AZD5004","slug":"azd5004","phase":"phase_2","mechanism":"AZD5004 is a selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) that blocks aberrant FGF signaling in hepatocellular carcinoma and other cancers.","indications":["Hepatocellular carcinoma (HCC), FGFR4-positive"],"catalyst":""},{"name":"AZD5004 film-coated tablet","genericName":"AZD5004 film-coated tablet","slug":"azd5004-film-coated-tablet","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD5055 film-coated tablet","genericName":"AZD5055 film-coated tablet","slug":"azd5055-film-coated-tablet","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD5122","genericName":"AZD5122","slug":"azd5122","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD5148","genericName":"AZD5148","slug":"azd5148","phase":"phase_2","mechanism":"AZD5148 is a selective, potent and orally bioavailable adenosine A2A receptor antagonist.","indications":["Multiple myeloma"],"catalyst":""},{"name":"AZD5213","genericName":"AZD5213","slug":"azd5213","phase":"phase_2","mechanism":"AZD5213 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"AZD5315","genericName":"AZD5315","slug":"azd5315","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AZD5335","genericName":"AZD5335","slug":"azd5335","phase":"phase_3","mechanism":"AZD5335 is a selective inhibitor of fibroblast growth factor receptor 1 (FGFR1) that blocks aberrant FGFR signaling in cancer cells.","indications":["FGFR1-amplified or FGFR1-driven solid tumors (in development)"],"catalyst":""},{"name":"AZD5363when combined with weekly paclitaxel.","genericName":"AZD5363when combined with weekly paclitaxel.","slug":"azd5363when-combined-with-weekly-paclitaxel","phase":"phase_1","mechanism":"ATR kinase inhibitor","indications":["Triple-negative breast cancer"],"catalyst":""},{"name":"AZD5438","genericName":"AZD5438","slug":"azd5438","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD5462 film-coated tablet","genericName":"AZD5462 film-coated tablet","slug":"azd5462-film-coated-tablet","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD5492","genericName":"AZD5492","slug":"azd5492","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD5634","genericName":"AZD5634","slug":"azd5634","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD5634 for infusion","genericName":"AZD5634 for infusion","slug":"azd5634-for-infusion","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD5634 for inhalation","genericName":"AZD5634 for inhalation","slug":"azd5634-for-inhalation","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD5718 IR tablet","genericName":"AZD5718 IR tablet","slug":"azd5718-ir-tablet","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD5718 tablet, Formulation B","genericName":"AZD5718 tablet, Formulation B","slug":"azd5718-tablet-formulation-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD5718 tablet, Formulation C","genericName":"AZD5718 tablet, Formulation C","slug":"azd5718-tablet-formulation-c","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD5851","genericName":"AZD5851","slug":"azd5851","phase":"phase_2","mechanism":"AZD5851 is a selective and potent inhibitor of the PI3K delta isoform.","indications":["Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)","Relapsed or refractory follicular lymphoma"],"catalyst":""},{"name":"AZD5863","genericName":"AZD5863","slug":"azd5863","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD6234 Formulation 1","genericName":"AZD6234 Formulation 1","slug":"azd6234-formulation-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD6234 Formulation 3","genericName":"AZD6234 Formulation 3","slug":"azd6234-formulation-3","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD6234 in combination with AZD9550","genericName":"AZD6234 in combination with AZD9550","slug":"azd6234-in-combination-with-azd9550","phase":"phase_2","mechanism":"AZD6234 is a PI3K inhibitor, and AZD9550 is a CDK9 inhibitor, which together target cancer cell growth and survival.","indications":["Metastatic non-small cell lung cancer"],"catalyst":""},{"name":"AZD6244 Dosing Period 1","genericName":"AZD6244 Dosing Period 1","slug":"azd6244-dosing-period-1","phase":"phase_1","mechanism":"MEK inhibitor","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"AZD6244 Dosing Period 2","genericName":"AZD6244 Dosing Period 2","slug":"azd6244-dosing-period-2","phase":"phase_1","mechanism":"MEK inhibitor","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"AZD6244 Dosing Period 3","genericName":"AZD6244 Dosing Period 3","slug":"azd6244-dosing-period-3","phase":"phase_1","mechanism":"MEK inhibitor","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"AZD6244 Dosing Period 4","genericName":"AZD6244 Dosing Period 4","slug":"azd6244-dosing-period-4","phase":"phase_1","mechanism":"AZD6244 is a selective inhibitor of MEK1/2, which are key components of the RAS-RAF-MEK-ERK signaling pathway.","indications":["Advanced solid tumors with RAS or BRAF mutations"],"catalyst":""},{"name":"AZD6370","genericName":"AZD6370","slug":"azd6370","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD6738 and olaparib","genericName":"AZD6738 and olaparib","slug":"azd6738-and-olaparib","phase":"phase_2","mechanism":"PARP inhibitor","indications":["Ovarian cancer","Breast cancer"],"catalyst":""},{"name":"AZD6750","genericName":"AZD6750","slug":"azd6750","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD7009, no generic name available","genericName":"AZD7009, no generic name available","slug":"azd7009-no-generic-name-available","phase":"phase_2","mechanism":"AZD7009 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","indications":["Moderate to severe atopic dermatitis"],"catalyst":""},{"name":"AZD7268","genericName":"AZD7268","slug":"azd7268","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD7503 Intervention","genericName":"AZD7503 Intervention","slug":"azd7503-intervention","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD7648","genericName":"AZD7648","slug":"azd7648","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD7789","genericName":"AZD7789","slug":"azd7789","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD8154","genericName":"AZD8154","slug":"azd8154","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD8205","genericName":"AZD8205","slug":"azd8205","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD8205 in combination with AZD9574","genericName":"AZD8205 in combination with AZD9574","slug":"azd8205-in-combination-with-azd9574","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD8233 subcutaneous injection","genericName":"AZD8233 subcutaneous injection","slug":"azd8233-subcutaneous-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD8309","genericName":"AZD8309","slug":"azd8309","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD8329","genericName":"AZD8329","slug":"azd8329","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD8330","genericName":"AZD8330","slug":"azd8330","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD8529","genericName":"AZD8529","slug":"azd8529","phase":"phase_2","mechanism":"AZD8529 is a selective adenosine A2A receptor antagonist.","indications":["Multiple myeloma"],"catalyst":""},{"name":"AZD8566 IV carbon labelled","genericName":"AZD8566 IV carbon labelled","slug":"azd8566-iv-carbon-labelled","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD8630","genericName":"AZD8630","slug":"azd8630","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD8835","genericName":"AZD8835","slug":"azd8835","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD8835 in combination with fulvestrant","genericName":"AZD8835 in combination with fulvestrant","slug":"azd8835-in-combination-with-fulvestrant","phase":"phase_1","mechanism":"AZD8835 is a selective and potent inhibitor of the androgen receptor.","indications":["Hormone receptor-positive breast cancer"],"catalyst":""},{"name":"AZD8871","genericName":"AZD8871","slug":"azd8871","phase":"phase_2","mechanism":"AZD8871 is a small molecule that targets the PI3K delta inhibitor.","indications":["Relapsed or refractory chronic lymphocytic leukemia (CLL)"],"catalyst":""},{"name":"AZD8871 100 µg","genericName":"AZD8871 100 µg","slug":"azd8871-100-g","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD8871 600 µg","genericName":"AZD8871 600 µg","slug":"azd8871-600-g","phase":"phase_2","mechanism":"AZD8871 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"AZD8931","genericName":"AZD8931","slug":"azd8931","phase":"phase_2","mechanism":"AZD8931 is a PI3K inhibitor.","indications":["Advanced solid tumours"],"catalyst":""},{"name":"AZD9150, Durvalumab","genericName":"AZD9150, Durvalumab","slug":"azd9150-durvalumab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD9291 tablets","genericName":"AZD9291 tablets","slug":"azd9291-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD9496 Variant A","genericName":"AZD9496 Variant A","slug":"azd9496-variant-a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD9496 Variant D","genericName":"AZD9496 Variant D","slug":"azd9496-variant-d","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD9550","genericName":"AZD9550","slug":"azd9550","phase":"phase_2","mechanism":"AZD9550 is a small molecule that acts as a selective and potent inhibitor of the PI3K delta (p110δ) subunit.","indications":["Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)","Relapsed or refractory follicular lymphoma"],"catalyst":""},{"name":"AZD9550 and AZD6234","genericName":"AZD9550 and AZD6234","slug":"azd9550-and-azd6234","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD9567 125 mg","genericName":"AZD9567 125 mg","slug":"azd9567-125-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD9567 20 mg","genericName":"AZD9567 20 mg","slug":"azd9567-20-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD9567 Monohydrat","genericName":"AZD9567 Monohydrat","slug":"azd9567-monohydrat","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD9742","genericName":"AZD9742","slug":"azd9742","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD9750","genericName":"AZD9750","slug":"azd9750","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD9773","genericName":"AZD9773","slug":"azd9773","phase":"phase_2","mechanism":"AZD9773 is a selective inhibitor of myeloid differentiation primary response 88 (MyD88) that blocks innate immune signaling to reduce inflammatory responses.","indications":["Systemic lupus erythematosus (SLE)","Other autoimmune/inflammatory conditions"],"catalyst":""},{"name":"AZD9819","genericName":"AZD9819","slug":"azd9819","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD9833","genericName":"AZD9833","slug":"azd9833","phase":"phase_3","mechanism":"AZD9833 is an oral selective estrogen receptor degrader (SERD) that binds to and degrades the estrogen receptor, blocking estrogen-driven cancer cell growth.","indications":["Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer","Hormone receptor-positive breast cancer in combination with CDK4/6 inhibitors"],"catalyst":""},{"name":"AZD9833 film-coated tablet A Dose 1","genericName":"AZD9833 film-coated tablet A Dose 1","slug":"azd9833-film-coated-tablet-a-dose-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD9833 film-coated tablet B Dose 1","genericName":"AZD9833 film-coated tablet B Dose 1","slug":"azd9833-film-coated-tablet-b-dose-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZD9833 with abemaciclib","genericName":"AZD9833 with abemaciclib","slug":"azd9833-with-abemaciclib","phase":"phase_1","mechanism":"AZD9833 is a CDK4/6 inhibitor, and abemaciclib is a CDK4/6 inhibitor.","indications":["Breast cancer"],"catalyst":""},{"name":"AZD9833 with anastrozole","genericName":"AZD9833 with anastrozole","slug":"azd9833-with-anastrozole","phase":"phase_1","mechanism":"Estrogen receptor inhibitor","indications":["Hormone receptor-positive breast cancer"],"catalyst":""},{"name":"AZD9833 with capivasertib","genericName":"AZD9833 with capivasertib","slug":"azd9833-with-capivasertib","phase":"phase_1","mechanism":"AZD9833 is a CDK4/6 inhibitor, and capivasertib is a pan-PI3K inhibitor.","indications":["Breast cancer"],"catalyst":""},{"name":"AZD9833 with everolimus","genericName":"AZD9833 with everolimus","slug":"azd9833-with-everolimus","phase":"phase_1","mechanism":"mTOR inhibitor","indications":["Breast cancer"],"catalyst":""},{"name":"AZD9833 with palbociclib","genericName":"AZD9833 with palbociclib","slug":"azd9833-with-palbociclib","phase":"phase_1","mechanism":"CDK4/6 inhibitor","indications":["Breast cancer"],"catalyst":""},{"name":"AZD9977, oral suspension","genericName":"AZD9977, oral suspension","slug":"azd9977-oral-suspension","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Abiraterone + Prednisolone/Prednisone","genericName":"Abiraterone + Prednisolone/Prednisone","slug":"abiraterone-prednisolone-prednisone","phase":"phase_3","mechanism":"Abiraterone inhibits CYP17A1 to block androgen synthesis, while prednisolone/prednisone suppresses ACTH-driven adrenal compensation and provides anti-inflammatory effects.","indications":["Metastatic castration-resistant prostate cancer (mCRPC)","High-risk metastatic hormone-sensitive prostate cancer (mHSPC)"],"catalyst":""},{"name":"Abraxane + carboplatin","genericName":"Abraxane + carboplatin","slug":"abraxane-carboplatin","phase":"phase_3","mechanism":"Abraxane (paclitaxel albumin-bound nanoparticles) stabilizes microtubules to halt cell division, while carboplatin creates DNA crosslinks to prevent replication, together providing synergistic cytotoxic effects against cancer cells.","indications":["Non-small cell lung cancer (NSCLC)","Ovarian cancer","Breast cancer","Other solid tumors (phase 3 dependent)"],"catalyst":""},{"name":"Acalabrutinib Treatment A","genericName":"Acalabrutinib Treatment A","slug":"acalabrutinib-treatment-a","phase":"phase_1","mechanism":"BTK inhibitor","indications":["Chronic lymphocytic leukemia","Mantle cell lymphoma"],"catalyst":""},{"name":"Acalabrutinib Treatment C","genericName":"Acalabrutinib Treatment C","slug":"acalabrutinib-treatment-c","phase":"phase_1","mechanism":"BTK inhibitor","indications":["Chronic lymphocytic leukemia","Mantle cell lymphoma"],"catalyst":""},{"name":"Acalabrutinib Treatment D","genericName":"Acalabrutinib Treatment D","slug":"acalabrutinib-treatment-d","phase":"phase_1","mechanism":"BTK inhibitor","indications":["Chronic lymphocytic leukemia","Mantle cell lymphoma"],"catalyst":""},{"name":"Acalabrutinib capsule","genericName":"Acalabrutinib capsule","slug":"acalabrutinib-capsule","phase":"marketed","mechanism":"Acalabrutinib is a selective inhibitor of Bruton's tyrosine kinase (BTK) that blocks B-cell proliferation and survival signaling in hematologic malignancies.","indications":["Chronic lymphocytic leukemia (CLL)","Small lymphocytic lymphoma (SLL)","Mantle cell lymphoma (MCL)","Marginal zone lymphoma (MZL)"],"catalyst":""},{"name":"Acalabrutinib combination with Rituximab","genericName":"Acalabrutinib combination with Rituximab","slug":"acalabrutinib-combination-with-rituximab","phase":"phase_2","mechanism":"BTK inhibitor","indications":["Chronic lymphocytic leukemia","Mantle cell lymphoma"],"catalyst":""},{"name":"Acalabrutinib monotherapy","genericName":"Acalabrutinib monotherapy","slug":"acalabrutinib-monotherapy","phase":"phase_2","mechanism":"Acalabrutinib inhibits Bruton's tyrosine kinase (BTK), which blocks B-cell activation and proliferation.","indications":["Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy","Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma"],"catalyst":""},{"name":"Acetylsalicylzuur Apotex Cardio","genericName":"Acetylsalicylzuur Apotex Cardio","slug":"acetylsalicylzuur-apotex-cardio","phase":"phase_1","mechanism":"Inhibits COX-1 and COX-2 enzymes","indications":["Cardiovascular disease prevention","Antiplatelet therapy"],"catalyst":""},{"name":"Aclidinium Bromide 200 µg","genericName":"Aclidinium Bromide 200 µg","slug":"aclidinium-bromide-200-g","phase":"phase_3","mechanism":"Aclidinium bromide is a long-acting muscarinic antagonist that blocks M3 receptors in airway smooth muscle to prevent bronchoconstriction and improve airflow.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance treatment"],"catalyst":""},{"name":"Aclidinium Bromide 400 µg","genericName":"Aclidinium Bromide 400 µg","slug":"aclidinium-bromide-400-g","phase":"phase_3","mechanism":"Aclidinium bromide is a muscarinic M3 receptor antagonist that blocks acetylcholine signaling in airway smooth muscle, causing bronchodilation.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance treatment"],"catalyst":""},{"name":"Aclidinium bromide and formoterol","genericName":"Aclidinium bromide and formoterol","slug":"aclidinium-bromide-and-formoterol","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Aclidinium bromide/formoterol fumarate combination","genericName":"Aclidinium bromide/formoterol fumarate combination","slug":"aclidinium-bromide-formoterol-fumarate-combination","phase":"marketed","mechanism":"Aclidinium bromide and formoterol fumarate work together as a long-acting anticholinergic and long-acting beta-2 agonist to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance treatment"],"catalyst":""},{"name":"Active Comparator: Olaparib tablets","genericName":"Active Comparator: Olaparib tablets","slug":"active-comparator-olaparib-tablets","phase":"phase_3","mechanism":"Olaparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and causing cell death, particularly in BRCA-mutant tumors.","indications":["BRCA-mutant metastatic breast cancer","BRCA-mutant ovarian cancer","BRCA-mutant pancreatic cancer","Homologous recombination deficiency-positive ovarian cancer (maintenance therapy)","Castration-resistant prostate cancer with HRD"],"catalyst":""},{"name":"Administration of AZD6738","genericName":"Administration of AZD6738","slug":"administration-of-azd6738","phase":"phase_1","mechanism":"AZD6738 is a selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase, which plays a critical role in the DNA damage response pathway.","indications":["Solid tumors with defective DNA damage response pathways"],"catalyst":""},{"name":"Administration of ceralasertib and olaparib","genericName":"Administration of ceralasertib and olaparib","slug":"administration-of-ceralasertib-and-olaparib","phase":"phase_1","mechanism":"PARP inhibitor","indications":["Breast cancer","Ovarian cancer"],"catalyst":""},{"name":"Administration of ceralasertib in combination with AZD5305","genericName":"Administration of ceralasertib in combination with AZD5305","slug":"administration-of-ceralasertib-in-combination-with-azd5305","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Administration of ceralasertib monotherapy","genericName":"Administration of ceralasertib monotherapy","slug":"administration-of-ceralasertib-monotherapy","phase":"phase_1","mechanism":"Ceralasertib is an ATP-competitive inhibitor of the serine/threonine kinase ATR, which is involved in DNA damage response pathways.","indications":["Advanced solid tumors"],"catalyst":""},{"name":"Albuterol and budesonide inhalation aerosol","genericName":"Albuterol and budesonide inhalation aerosol","slug":"albuterol-and-budesonide-inhalation-aerosol","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Anastozole (Arimidex)","genericName":"Anastozole (Arimidex)","slug":"anastozole-arimidex","phase":"phase_3","mechanism":"Anastrozole is a non-steroidal aromatase inhibitor that blocks the conversion of androgens to estrogen in postmenopausal women with hormone receptor-positive breast cancer.","indications":["Adjuvant treatment of hormone receptor-positive early-stage breast cancer in postmenopausal women","First-line treatment of advanced breast cancer in postmenopausal women","Extended therapy following tamoxifen in postmenopausal women with early-stage breast cancer"],"catalyst":""},{"name":"Anastrazole","genericName":"Anastrazole","slug":"anastrazole","phase":"marketed","mechanism":"Aromatase","indications":["Hormone receptor positive malignant neoplasm of breast"],"catalyst":""},{"name":"Anastrazole (Arimidex)","genericName":"Anastrazole (Arimidex)","slug":"anastrazole-arimidex","phase":"phase_3","mechanism":"Anastrozole is a non-steroidal aromatase inhibitor that blocks the conversion of androgens to estrogen in postmenopausal women with hormone receptor-positive breast cancer.","indications":["Adjuvant treatment of hormone receptor-positive early-stage breast cancer in postmenopausal women","First-line treatment of advanced breast cancer in postmenopausal women","Extended therapy following tamoxifen in postmenopausal women with early-stage breast cancer"],"catalyst":""},{"name":"Anastrozole and goserelin","genericName":"Anastrozole and goserelin","slug":"anastrozole-and-goserelin","phase":"phase_2","mechanism":"Aromatase inhibitor","indications":["Breast cancer"],"catalyst":""},{"name":"Anoro® Ellipta®","genericName":"Anoro® Ellipta®","slug":"anoro-ellipta","phase":"marketed","mechanism":"Anoro Ellipta combines a long-acting beta-2 agonist and a long-acting muscarinic antagonist to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance treatment"],"catalyst":""},{"name":"Auto-injector with exenatide suspension","genericName":"Auto-injector with exenatide suspension","slug":"auto-injector-with-exenatide-suspension","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BEYFORTUS","genericName":"NIRSEVIMAB-ALIP","slug":"nirsevimab-alip","phase":"marketed","mechanism":"Fusion glycoprotein F0","indications":["Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease"],"catalyst":""},{"name":"Baxdrostat and dapagliflozin","genericName":"Baxdrostat and dapagliflozin","slug":"baxdrostat-and-dapagliflozin","phase":"phase_3","mechanism":"Baxdrostat inhibits aldosterone synthase to reduce aldosterone production, while dapagliflozin inhibits SGLT2 to increase urinary glucose excretion, together addressing both hypertension/heart failure and glycemic control.","indications":["Heart failure with reduced ejection fraction","Hypertension with cardiometabolic disease"],"catalyst":""},{"name":"Baxdrostat/dapagliflozin","genericName":"Baxdrostat/dapagliflozin","slug":"baxdrostat-dapagliflozin","phase":"phase_3","mechanism":"Baxdrostat inhibits aldosterone synthase to reduce aldosterone production, while dapagliflozin inhibits SGLT2 to increase urinary glucose excretion and reduce sodium reabsorption.","indications":["Heart failure with reduced ejection fraction","Chronic kidney disease"],"catalyst":""},{"name":"Benralizumab (Medi-563)","genericName":"Benralizumab (Medi-563)","slug":"benralizumab-medi-563","phase":"phase_3","mechanism":"Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation.","indications":["Moderate-to-severe eosinophilic asthma","Severe eosinophilic granulomatosis with polyangiitis (EGPA)"],"catalyst":""},{"name":"Benralizumab Arm A","genericName":"Benralizumab Arm A","slug":"benralizumab-arm-a","phase":"phase_3","mechanism":"Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation.","indications":["Severe eosinophilic asthma","Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype)","Eosinophilic granulomatosis with polyangiitis (EGPA)"],"catalyst":""},{"name":"Benralizumab Arm B","genericName":"Benralizumab Arm B","slug":"benralizumab-arm-b","phase":"phase_3","mechanism":"Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduced airway inflammation.","indications":["Moderate-to-severe eosinophilic asthma","Severe asthma with eosinophilic phenotype"],"catalyst":""},{"name":"Benralizumab Arm C","genericName":"Benralizumab Arm C","slug":"benralizumab-arm-c","phase":"phase_3","mechanism":"Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation.","indications":["Severe eosinophilic asthma","Eosinophilic granulomatosis with polyangiitis (EGPA)"],"catalyst":""},{"name":"Biological: AZD3152","genericName":"Biological: AZD3152","slug":"biological-azd3152","phase":"phase_2","mechanism":"AZD3152 is a monoclonal antibody targeting PD-L1.","indications":["Non-small cell lung cancer","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"Biological: Experimental: Tezepelumab","genericName":"Biological: Experimental: Tezepelumab","slug":"biological-experimental-tezepelumab","phase":"phase_3","mechanism":"Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), a key upstream cytokine in type 2 inflammation.","indications":["Moderate-to-severe asthma (type 2 inflammation)","Atopic dermatitis"],"catalyst":""},{"name":"Brilinta","genericName":"Brilinta","slug":"brilinta","phase":"marketed","mechanism":"Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12","indications":["Acute coronary syndrome","Myocardial Reinfarction Prevention","Percutaneous coronary intervention","Peripheral vascular disease"],"catalyst":""},{"name":"Budesonide 200 microgram","genericName":"Budesonide 200 microgram","slug":"budesonide-200-microgram","phase":"phase_2","mechanism":"Budesonide is a corticosteroid that works by inhibiting the release of pro-inflammatory mediators from mast cells and other cells.","indications":["Maintenance treatment of asthma","Ultrasonographically active inflammatory lesions of Crohn's disease"],"catalyst":""},{"name":"Budesonide CFC","genericName":"Budesonide CFC","slug":"budesonide-cfc","phase":"phase_3","mechanism":"Budesonide is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in the lungs.","indications":["Asthma (maintenance and prevention)","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Budesonide HFA","genericName":"Budesonide HFA","slug":"budesonide-hfa","phase":"phase_3","mechanism":"Budesonide is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Budesonide HFA pMDI","genericName":"Budesonide HFA pMDI","slug":"budesonide-hfa-pmdi","phase":"phase_3","mechanism":"Budesonide is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Budesonide Turbuhaler 200 µg","genericName":"Budesonide Turbuhaler 200 µg","slug":"budesonide-turbuhaler-200-g","phase":"phase_3","mechanism":"Budesonide is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Budesonide inhalation suspension","genericName":"Budesonide inhalation suspension","slug":"budesonide-inhalation-suspension","phase":"marketed","mechanism":"Budesonide is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production.","indications":["Asthma maintenance therapy in children and adults","Croup (laryngotracheobronchitis)"],"catalyst":""},{"name":"Budesonide pMDI","genericName":"Budesonide pMDI","slug":"budesonide-pmdi","phase":"phase_3","mechanism":"Budesonide is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production.","indications":["Asthma (maintenance and reliever therapy)","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-01","type":"earnings","headline":"AstraZeneca Reports Fourth-Quarter and Full-Year 2023 Results","summary":"AstraZeneca reported fourth-quarter and full-year 2023 results, with revenue of $13.4 billion and a net loss of $1.2 billion.","drugName":"","sentiment":"neutral"},{"date":"2023-09-01","type":"deal","headline":"AstraZeneca and Merck Announce Collaboration to Develop and Commercialize LYNPARZA","summary":"AstraZeneca and Merck announced a collaboration to develop and commercialize LYNPARZA, a PARP inhibitor for the treatment of certain types of cancer.","drugName":"","sentiment":"positive"},{"date":"2023-06-01","type":"regulatory","headline":"FDA Approves AstraZeneca's Tagrisso for First-Line Treatment of EGFR-Mutated NSCLC","summary":"The FDA approved AstraZeneca's Tagrisso for the first-line treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC).","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-02","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: IMFINZI+IMJUDO IMPROVES PFS IN EARLY LIVER CANCER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-04-01","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: TOTAL VOTING RIGHTS AND ADMISSION OF SHARES","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: EFZIMFOTASE ALFA PH3 PROGRAM SHOW POSITIVE RESULTS","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-27","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: TOZORAKIMAB MET OBERON/TITANIA PRIMARY ENDPOINTS","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-20","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: NOTIFICATION OF ADMISSION OF SHARES","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-16","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: IMFINZI APPROVED IN EU FOR EARLY GASTRIC CANCER","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-10","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: NOTICE OF AGM","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-10","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-06","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: DIRECTOR/PDMR SHAREHOLDING","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-06","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: DIRECTOR/PDMR SHAREHOLDING","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-06","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: DIRECTOR/PDMR SHAREHOLDING","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-02","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-02","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: TOTAL VOTING RIGHTS","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: ASTRAZENECA PRICES A $2BN BOND OFFERING","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-02-25","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FILING OF FORM 20-F WITH SEC","headline":"6-K Filing","sentiment":"neutral"}],"patents":[{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"9119863","type":"Method of Use","expiryDate":"2026-11-09","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"8975243","type":"Method of Use","expiryDate":"2026-11-09","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"8497258","type":"Method of Use","expiryDate":"2026-11-09","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"11197822","type":"Formulation","expiryDate":"2026-11-09","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"11413296","type":"Formulation","expiryDate":"2026-11-09","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"8679545","type":"Formulation","expiryDate":"2026-11-09","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Prilosec","drugSlug":"omeprazole","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1500000000},{"drugName":"Lynparza","drugSlug":"olaparib","patentNumber":"8247416","type":"Compound","expiryDate":"2028-09-24","territory":"US","annualRevenue":2600000000,"genericFilings":[]},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"11357859","type":"Method of Use","expiryDate":"2028-11-12","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"10293052","type":"Formulation","expiryDate":"2028-11-22","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"8491932","type":"Formulation","expiryDate":"2029-05-07","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Arimidex","drugSlug":"anastrozole","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"9050368","type":"Formulation","expiryDate":"2029-08-01","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"8324192","type":"Method of Use","expiryDate":"2029-08-03","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Brilinta","drugSlug":"ticagrelor","patentNumber":"8425934","type":"Formulation","expiryDate":"2030-04-17","territory":"US","annualRevenue":1100000000,"genericFilings":[]},{"drugName":"Brilinta","drugSlug":"ticagrelor","patentNumber":"8425934*PED","type":"Compound","expiryDate":"2030-10-17","territory":"US","annualRevenue":1100000000,"genericFilings":[]},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"9192581","type":"Formulation","expiryDate":"2031-09-07","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"8895064","type":"Formulation","expiryDate":"2031-09-07","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"10660858","type":"Formulation","expiryDate":"2031-09-07","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"10307375","type":"Formulation","expiryDate":"2031-09-07","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"9132093","type":"Formulation","expiryDate":"2031-09-07","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Faslodex","drugSlug":"fulvestrant","patentNumber":"9833459","type":"Formulation","expiryDate":"2034-02-14","territory":"US","genericFilings":[]},{"drugName":"Faslodex","drugSlug":"fulvestrant","patentNumber":"10188663","type":"Formulation","expiryDate":"2034-02-14","territory":"US","genericFilings":[]},{"drugName":"Faslodex","drugSlug":"fulvestrant","patentNumber":"9271990","type":"Formulation","expiryDate":"2034-05-17","territory":"US","genericFilings":[]},{"drugName":"Nexium","drugSlug":"esomeprazole","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":2500000000},{"drugName":"Brilinta","drugSlug":"ticagrelor","patentNumber":"10300065","type":"Method of Use","expiryDate":"2036-01-27","territory":"US","annualRevenue":1100000000,"genericFilings":[]},{"drugName":"Brilinta","drugSlug":"ticagrelor","patentNumber":"10300065*PED","type":"Compound","expiryDate":"2036-07-27","territory":"US","annualRevenue":1100000000,"genericFilings":[]},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"9707182","type":"Formulation","expiryDate":"2036-09-09","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"10172802","type":"Method of Use","expiryDate":"2036-09-09","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Prilosec","drugSlug":"omeprazole","patentNumber":"10835488","type":"Formulation","expiryDate":"2036-12-08","territory":"US","annualRevenue":1041000000,"genericFilings":[]},{"drugName":"Prilosec","drugSlug":"omeprazole","patentNumber":"10076494","type":"Formulation","expiryDate":"2036-12-08","territory":"US","annualRevenue":1041000000,"genericFilings":[]},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"11564934","type":"Method of Use","expiryDate":"2039-01-10","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"11260064","type":"Formulation","expiryDate":"2039-01-10","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"11896719","type":"Method of Use","expiryDate":"2043-01-23","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"12171882","type":"Method of Use","expiryDate":"2043-01-23","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"12311057","type":"Formulation","expiryDate":"2043-01-23","territory":"US","annualRevenue":2800000000,"genericFilings":[]},{"drugName":"Pulmicort Respules","drugSlug":"budesonide","patentNumber":"12171883","type":"Formulation","expiryDate":"2043-01-23","territory":"US","annualRevenue":2800000000,"genericFilings":[]}],"drugCount":300,"phaseCounts":{"marketed":46,"phase_3":51,"phase_2":65,"phase_1":137,"discontinued":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Pfizer","Merck","GSK"],"therapeuticFocus":["Oncology","Cardiovascular, Renal & Metabolism","Respiratory"],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":null,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":204.91,"previousClose":200.81,"fiftyTwoWeekHigh":212.71,"fiftyTwoWeekLow":122.48,"fiftyTwoWeekRange":"122.48 - 212.71","fiftyDayAverage":195.11,"twoHundredDayAverage":172.01,"beta":0.28,"enterpriseValue":335473836032,"forwardPE":34.4,"priceToBook":6.53,"priceToSales":5.41,"enterpriseToRevenue":5.71,"enterpriseToEbitda":17.4,"pegRatio":1.67,"ebitda":19279998976,"ebitdaMargin":32.8,"freeCashflow":7865375232,"operatingCashflow":14574999552,"totalDebt":29703000064,"debtToEquity":61,"currentRatio":0.94,"returnOnAssets":8.2,"returnOnEquity":22.8,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":10,"targetMeanPrice":209.89,"targetHighPrice":240,"targetLowPrice":120,"dividendRate":3.16,"payoutRatio":0.48,"fiveYearAvgDividendYield":2.13,"exDividendDate":1771545600,"insiderHeldPercent":0,"institutionHeldPercent":57.2,"sharesOutstanding":1550283527,"floatShares":1543370514,"sharesShort":2380486,"shortRatio":0.99,"shortPercentOfFloat":0,"epsTrailing":6.55,"epsForward":5.96,"revenuePerShare":37.9,"bookValue":31.38,"officers":[{"age":66,"name":"Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.","title":"CEO & Executive Director"},{"age":51,"name":"Dr. Aradhana  Sarin M.D.","title":"CFO & Executive Director"},{"age":55,"name":"Ms. Pam P. Cheng","title":"EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board"},{"age":null,"name":"Mr. Joris  Silon","title":"Head of Investor Relations"},{"age":null,"name":"Mr. Jeffrey  Pott J.D.","title":"CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board"},{"age":null,"name":"Dr. Ruud  Dobber Ph.D.","title":"Executive Vice-President of BioPharmaceuticals Business Unit"},{"age":59,"name":"Dr. Susan Mary Galbraith M.D., Ph.D.","title":"Executive Vice President of Oncology R&D"},{"age":null,"name":"Ms. Iskra  Reic","title":"Executive Vice President of International"}],"industry":"Drug Manufacturers - General","irWebsite":"","website":"https://www.astrazeneca.com","phone":"44 20 3749 5000"}}